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A B S TR A C T
The tumour vascular network is essential for tumour growth. Over the next few 
years, the use of vascular targeting drugs in the treatment of patients with cancer 
will escalate, which in turn will increase demand for non-invasive methods of 
assessing tumour vasculature. A perfusion CT technique was developed, 
allowing measurement of tumour vascular leakage (K) and blood volume (BV) of 
entire large tumours. This technique is shown to improve on measurement 
repeatability compared to conventional single level techniques, and can be used 
to measure tumour vascular changes following anti-cancer treatment.
Ionising radiation has been shown to act synergistically with the vascular 
disrupting agent Combretastatin A4 Phosphate (CA4P) in animal tumour models. 
Patients with advanced non-small cell lung cancer were treated with fractionated 
radiotherapy in combination with CA4P. Radiation alone increases tumour K and 
BV, especially at the tumour rim, and appears to enhance the vascular disrupting 
activity of CA4P. The increase in K after radiotherapy correlates with subsequent 
decrease in BV after CA4P, and a sustained reduction in tumour BV was 
achieved with this combination.
Nitric oxide (NO) is an important signalling molecule responsible for maintaining 
the vasodilator tone in tumour vessels, as well as having pro-angiogenic 
properties. As part of a phase I study, patients with cancer were treated with the
3
nitric oxide synthase inhibitor N-nitro L-arginine (LNNA). Patients with 
measurable tumours were scanned using perfusion CT, and all patients 
demonstrated sustained reductions in tumour BV, demonstrating for the first time 
in man that NO inhibition has tumour anti-vascular activity.
In summary, perfusion CT is a repeatable technique that can be used to measure 
vascular changes in whole tumours following therapy. The results presented here 
have provided further evidence that targeting the tumour vasculature is a 
promising approach in the treatment of cancer.
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Figure 3.2 Bland-Altman agreement plot (a) of the difference between the two 
scans against the mean of the transfer constant (K) values from the 
two scans. The mean difference is indicated by the solid line. The 
two outer dotted lines represent the 95% limits of agreement, which 
define the range within which most differences between repeated K 
measurements made on the same subject will lie. Scatter plot (b) of 
K measurements from the two scans, with a line of perfect 
agreement, which represents the line all points would lie on if both 
measurements gave the same reading. This plot provides a visual 
demonstration of how precise the two sets of measurements are. 
The closer the measurements lie to this line of equality, the better 
the agreement.
Figure 3.3 Bland-Altman agreement plot (a) of the difference between the two 
scans against the mean of the blood volume (BV) values from the 
two scans. The mean difference is indicated by the solid line. The 
two outer dotted lines represent the 95% limits of agreement, which 
define the range within which most differences between repeated 
BV measurements made on the same subject will lie. Scatter plot 
(b) of BV measurements from the two scans, with a line of perfect 
agreement, which represents the line all points would lie on if both 
measurements gave the same reading. This plot provides a visual 
demonstration of how precise the two sets of measurements are.
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from the two scans with a line of perfect agreement, for a 10mm, 
40mm and whole tumour coverage. As tumour coverage increases 
from 10mm to 40mm to whole tumour, the measurements become 
closer to the line of equality, indicating an improvement in 
agreement, and hence the precision of the measurements.
Line graphs showing mean changes (±1 standard error) in whole 
tumour vascular blood volume (BV) (a) and transfer constant (K) (b) 
after fractionated radiotherapy. Measurements are derived from 
pixel-by-pixel analysis of whole lung tumour volumes and included 
pixels from both the more vascularised tumour rim as well as the 
relatively poorly perfused tumour centre.
Coloured parametric maps depicting vascular blood volume (BV) at 
three contiguous axial levels from a lung tumour, at baseline (a) 
and after four fractions (18Gy total dose) of radiation therapy (b). 
Baseline tumour vascularity was spatially heterogeneous with the 
tumour rim being more vascular than the centre. A greater 
increase in BV after radiotherapy is observed at the tumour rim 
compared to the centre.
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showing coloured parametric map of transfer constant (K) at 
baseline (a) and after two fractions (9Gy total dose) of radiotherapy 
(b). Increases in K were seen predominantly at the rim of the 
tumour.
CT images of a lung tumour from three representative axial levels 
showing coloured parametric map of tumour blood volume (BV) 
before CA4P (a), 4 hours (b), and 72 hours (c) after a single dose 
of CA4P. Reduction in BV seen after CA4P at 4 hours was 
sustained to 72 hours and most evident at the tumour rim.
Line graphs showing individual changes in tumour transfer constant 
(K) after two fractions of radiotherapy (RT) (a), and tumour blood 
volume (BV) at four and 72 hours after combretastatin A4 
Phosphate (CA4P) (b). The six patients who had increases in K 
after RT had a vascular response to CA4P
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(BV) after combretastatin A4 Phosphate (CA4P) against change in 
the transfer constant (K) after radiotherapy. Increase in K after 
radiotherapy correlated to reduction in BV after CA4P (r=0.77, 
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Coloured parametric maps of tumour blood volume (BV) 
representing three contiguous axial levels of a lung tumour before
(a), and one hour after a single 0.5mg/kg infusion of N-nitro L- 
arginine (L-NNA) (b). Each pixel within the tumour map represents 
a single vascular parameter value; the colour scale indicates red 
pixels as high BV values and purple pixels as low BV values.
Line graph showing tumour vascular changes for all eight patients 
at baseline and one hour after N-nitro L-arginine (L-NNA) and the 
corresponding boxplots at baseline, one hour and 24 hours after L- 
NNA for blood volume (BV) (a), percentage of non-enhancing pixels
(b), and transfer constant (K) (c). Significant reductions in BV and 
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CHAPTER 1
INTRODUCTION
1.1 Targeting the tumour vasculature
The tumour vasculature is an attractive target for anti-cancer therapy for several 
reasons. First, tumour cells rely on an intact vascular network for survival. The 
tumour blood supply provides oxygen and nutrients and enables removal of toxic 
waste products. Solid tumours cannot grow and metastasise without their own 
blood supply. Second, tumour vessels are readily accessible to blood-borne anti­
cancer agents, as the cells to be targeted are next to the blood stream. This 
minimises problems with drug delivery. Third, a single tumour vessel might 
provide the blood supply for thousands of tumour cells, and theoretically, 
blockage or destruction of this single vessel will lead to significant tumour cell 
death downstream. Finally, endothelial cells that line tumour blood vessels have 
not undergone malignant transformation, and are less likely to become drug 
resistant due to genetic mutations.
Drugs that target the tumour vasculature are broadly divided into anti-angiogenic 
agents that prevent new vessel formation, and vascular disrupting agents that 
selectively destroy existing tumour vessels. There is also evidence that 
conventional treatment modalities such as radiotherapy and chemotherapy have 
vascular effects that contribute to their anti-tumour activity. Over the next few
years, there will be an increase in the number of vascular targeting drugs that 
enter the clinic, which will provide the impetus for further development of non- 
invasive methods of assessing the tumour vascularity in vivo. Functional imaging 
using computed tomography (CT), magnetic resonance imaging (MRI), and 
positron emission tomography (PET), can be used to measure surrogate markers 
of tumour vascular physiology including blood flow, blood volume, and 
permeability, and thus provide the clinical tools needed to study the tumour 
vascular environment.
The aim of this work is to measure the vascular changes that occur in human 
tumours after anti-cancer therapy using a novel functional CT technique. It is 
hoped that this work will contribute to increasing our understanding of tumour 
vascular biology, the role of the tumour vasculature in cancer, and lead to the 
development of novel strategies in cancer therapy.
1.2 Tumour vascular biology
Most solid tumours begin as an avascular group of cells relying on simple 
diffusion as a means of acquiring nutrition. In order for tumours to grow beyond a 
few millimetres in diameter, they need to develop their own viable blood supply, 
which is essential to the process of tumour growth, proliferation, and metastasis 
(Folkman 1992). The process of tumour neo-vascularisation involves 
angiogenesis, the development of new vessels by sprouting from pre-existing
ones, and possibly vasculogenesis, de novo vascular formation through the 
recruitment of circulating endothelial progenitor cells. The tumour vasculature is 
morphologically and functionally distinct. Tumour vessels are thin and tortuous, 
and are characterised by a relatively high endothelial cell proliferation rate, 
incomplete endothelium, relative absence of smooth muscle or pericyte 
investiture, hyper-permeability, high interstitial fluid pressure, and spatially and 
temporally heterogeneous microcirculation (Jain 1987, Boucher et al 1990, 
Dvorak et al 1991, Eberhard et al 2000, Hashizume et al 2000, Baluk et al 2003).
1.2.1 Tumour angiogenesis
Tumour angiogenesis is believed to be regulated by a dynamic balance between 
pro-angiogenic and anti-angiogenic factors. The initiation of tumour angiogenesis 
involves the switch to an angiogenic phenotype (Hanahan and Folkman 1996). 
This angiogenic switch can be triggered by the activation of oncogenes, and 
inactivation of tumour suppressor genes. The tumour microenvironment also 
plays a part in disrupting this tightly regulated equilibrium, and hypoxia, glucose 
deprivation, and low pH, can lead to the initiation of angiogenesis (Raben et al 
2003). Cancer cells stimulate angiogenesis by the increased production of pro- 
angiogenic factors, and a decrease in the physiologic levels of endogenous anti- 
angiogenic factors. The overall process of tumour angiogenesis involves the 
breakdown of basement membrane and the extracellular matrix by matrix 
metalloproteinase enzymes (MMP), migration and proliferation of endothelial
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cells, organisation of endothelial cells into hollow tubes, formation of new 
networks of blood vessels, and investment with smooth muscle cells or pericytes.
Regulators involved in inducing angiogenesis include vascular endothelial growth 
factor (VEGF), acidic and basic fibroblast growth factors (FGF), platelet derived 
growth factor (PDGF), angiopoietins (Ang-1 and Ang-2), epidermal growth factor 
(EGF), placental growth factor (PIGF), interleukin-8, integrins, and tumour 
necrosis factor alpha (TNF-a). PDGF is produced by endothelial and other cells 
and plays a central role in the recruitment of pericytes and smooth muscle cells 
(Gerhardt and Betsholtz 2003). The angiopoietins are ligands to the vascular 
specific receptor tyrosine kinase Tie-2, which when activated, stabilises the 
growing neovascular network (Thurston 2003). Integrins are present on 
endothelial cells and mediate endothelial cell-extracellular matrix interactions, 
adhesion and migration (Flodivala-Dilke et al 2003). Some of the known naturally 
occurring inhibitors of angiogenesis include thrombospondin-1 (TSP-1), 
angiostatin, endostatin, transforming growth factor beta (TGF-P), and tissue 
inhibitor of metalloproteinase-1, -2, and -3 (TIMP-1, TIMP-2 and TIMP-3).
VEGF is probably the most widely studied pro-angiogenic factor (Veikkola et al
2000). The VEGF molecule is a homodimer glycoprotein with several different 
isoforms, which mediates angiogenesis by acting on high affinity transmembrane 
tyrosine kinase receptors. VEGFR-1 and VEGFR-2 are found on vascular 
endothelial cells while VEGFR-3 is expressed on the lymphatic endothelium.
Originally identified as vascular permeability factor (Senger et al 1983), VEGF 
promotes angiogenesis by inducing capillary vessel permeability allowing plasma 
proteins such as fibrin to leak into the extravascular space, leading to clotting of 
extravasated fibrinogen and introduction of a provisional plasma-derived matrix. 
This provides a favourable environment for activated endothelial cells to migrate 
into and proliferate, once basement membrane breakdown has occurred. 
Functional vessels subsequently result from re-canalisation of these endothelial 
cells (Veikkola et al 2000).
1.2.2 The role of nitric oxide
Furchgott and Zawadzki (1980) first described the significance of endothelial 
cells in arterial smooth muscle relaxation, and hypothesised that the vasodilatory 
properties of acetylcholine were dependent on the release of a substance from 
endothelial cells termed endothelium derived relaxing factor (EDRF). Moncada 
and colleagues (Palmer et al 1987) demonstrated that nitric oxide (NO) released 
from vascular endothelial cells is indistinguishable from EDRF in terms of 
biological activity, stabilisation by superoxide dismutase, and susceptibility to 
inhibition by haemoglobin. They went on to identify L-arginine as the precursor to 
the synthesis of NO, as well as the enzyme nitric oxide synthase (NOS), which is 
able to generate NO and L-citrulline from L-arginine (Moncada et al 1989).
NO is now recognised as a ubiquitous signalling molecule that is implicated in a 
wide range of pathological and physiological processes. The formation of NO
from arginine is catalysed by the nitric oxide synthase (NOS) enzymes (Alderton 
et al 2001) (Figure 1.1).
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Figure 1.1 Synthesis of NO and citrulline from arginine catalysed by the 
enzyme nitric oxide synthase (NOS)
Three distinct isoforms of NOS have been identified: neuronal NOS (nNOS, also 
known as NOS1), inducible NOS (iNOS, also NOS2), and endothelial NOS 
(eNOS, also NOS3). nNOS and eNOS are constitutively expressed enzymes 
(cNOS), that are activated by increased intracellular concentrations of calcium 
(C a2+). C a2+ binds to calmodulin and the resulting complex activates nNOS or 
eNOS to produce low levels of NO, which mediates several physiological 
processes by activation of guanylate cyclase, causing an increase in cGMP. 
iNOS contains tightly bound calmodulin and is not dependent on intracellular 
Ca2\  Transcription of the iNOS gene is induced by inflammatory cytokines
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(including TNFa and IFNy), endotoxins, hypoxia and oxidative stress to produce 
physiologically high levels of NO. Inhibitory cytokines include TGF(3, IL-4, IL-10, 
and macrophage deactivating factor (MDF). In general, NO derived from eNOS 
has been implicated in tumour angiogenesis, as well as maintaining the 
vasodilator tone of tumour blood vessels, while iNOS induced NO mediates 
neoplastic transformation.
The biological role of NO in tumourigenesis is complex and NO has been 
implicated in both inhibition and promotion of tumour growth (Fukumara et al 
2006, Bonavida et al 2006) (Figure 1.2). The actions of NO appear to be 
dependent on its local concentration, cell type, cellular genetics and redox status. 
NO can induce tumour progression directly through induction of DNA damage, 
tumour cell invasion, proliferation, and migration, and indirectly through increased 
tumour blood flow and angiogenesis. On the other hand, high levels of NO are 
cytotoxic and can induce tumour cell apoptosis. Increased expression of NOS 
has been demonstrated in experimental tumour models, and higher levels of 
NOS expression in human tumours may be correlated with worse prognosis 
(Thomsen et al 1994, Cobbs et al 1995, Vakkala et al 2000, Klotz et al 1998, 
Fujimoto et al 1997, Gallo et al 1998).
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Figure 1.2 Mechanism of action of NO on the tumour vasculature and 
tumour cells resulting in both tumour progression (a), and 
tumour regression (b).
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NO plays an important role in tumour vascular biology. NO induces endothelial 
cell proliferation, migration and differentiation (Ziche et al 1994, Kawasaki et al 
2003). It has been shown to modulate blood flow and maintain the vasodilator 
tone of tumour vessels (Peterson 1991). NO is known to act downstream from 
many pro-angiogenic factors including VEGF which activate endothelial NOS in 
vascular endothelial cells (Ziche et al 1997, Veikkola et al 2000. Fukumara et al
2001). NO mediates VEGF induced hyper-permeability in tumour vessels and 
contributes to the development of the extracellular matrix (Fukumara et al 2001). 
NO might also have a role in the regulation of endogenous inhibitors of 
angiogenesis, and low levels of NO have been shown to suppress TSP-1 
expression (Ridnour et al 2005).
NO delivered exogenously from NO donor agents or by endogenous induction, 
has been reported as a hypoxic cell radiosensitiser and also as a radiosensitiser 
of oxygenated cells, which might be due to an increase in DNA damage 
mediated by reactive oxygen and nitrogen species (Mitchell et al 1993, Griffin et 
al 1996, Janssens et al 1998, Policastro et al 2006). The vasodilatory effects of 
NO may also contribute to increasing oxygenation of hypoxic tumour cells and 
enhancing radiotherapeutic efficacy. NO has also been found to mediate 
chemosensitivity in tumour cells, and hypoxia-induced drug resistance appears to 
result, in part, from downstream suppression of endogenous NO production 
(Matthews et al 2001). NO mimetics have been shown to reduce 
chemoresistance to doxorubicin in breast and prostate cancer cells (Frederiksen
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et al 2003, Muir et al 2006). NO induced vasodilatation may also improve 
cytotoxic drug delivery to tumours. However, the potential therapeutic role of NO 
and NOS inhibition in cancer patients remains to be evaluated.
1.3 Vascular targeting drugs
1.3.1 A brief history
It was first suggested more than 160 years ago, that the tumour vasculature was 
a potential target for the treatment of cancer. It was reported that occasionally, 
solid tumours could be eradicated when their circulation was interrupted (Walshe 
1844). In the 1970s, Folkman and colleagues hypothesised that tumours needed 
to develop their own blood supply in order to grow, and that tumour growth could 
be arrested if the factors promoting angiogenesis could be blocked (Folkman 
1971). A soluble factor was isolated from animal and human tumours, which was 
termed tumour-angiogenic factor, and shown to be mitogenic to endothelial cells 
and responsible for formation of new capillaries (Folkman et al 1971). It is now 
well recognised that tumour angiogenesis is a critical event in tumour growth and 
this has led to the identification of a large number of pro-angiogenic growth 
factors that can act directly on surface receptors on the vascular endothelium 
(e.g. vascular endothelial growth factor, VEGF), or indirectly via other cell types 
to activate further growth factor production (e.g. transforming growth factor-p, 
TGF-p). The VEGF-neutralising antibody bevacizumab was the first anti- 
angiogenic agent to be approved by the United States Food and Drug
30
Administration (FDA) in February 2004, although in the United Kingdom, it is not 
currently recommended by the National Institute for Health and Clinical 
Excellence (NICE).
In the early 1980s, Denekamp proposed that it might be possible to exploit the 
functional and morphological differences between tumour and normal blood 
vessels and therefore selectively target the existing tumour blood supply. It was 
also suggested that the anti-tumour effects of radiation and cytotoxic drugs could 
be partially due to damage to the tumour vasculature (Denekamp 1982 and 
1984). Distinct from anti-angiogenic agents, which aim to prevent tumour neo- 
vascularisation. vascular disrupting agents (VDA) aim to cause a rapid shutdown 
of the established vasculature, resulting in secondary tumour cell death. Two 
classes of VDAs are being developed. Ligand-directed VDAs use antibodies or 
peptides to target markers on the tumour endothelium which are selectively up- 
regulated. These markers include molecules involved with angiogenesis, cell 
adhesion, and pro-thrombotic change. Low molecular weight VDAs exploit the 
differences between normal and tumour endothelium to induce vascular 
shutdown of tumour blood vessels. Several low molecular weight VDAs are 
currently in clinical trials including the tubulin binding drugs, combretastatin A4 
phosphate (CA4P), Oxi 4503 and ZD6126, and the flavanoid, 5,6- 
dimethylxanthenone-4-acetic acid (DMXAA). These are more advanced in clinical 
development and will be discussed in greater detail in a later section.
1.3.2 Anti-angiogenic agents
The anti-angiogenic approach involves blocking the ability of endothelial cells to 
break down the surrounding matrix, inhibiting normal endothelial cells directly, 
and blocking factors that stimulate angiogenesis. Clinical strategies to interfere 
with VEGF signalling include the use of neutralising antibodies (e.g. 
Bevacizumab), the VEGF trap which uses a soluble VEGF receptor, and 
inhibition of the VEGF receptor tyrosine kinase (e.g. ZD6474). A list of anti- 
angiogenic agents in clinical trials is shown in Table 1.1 (from the United States 
National Cancer Institute, http://www.cancer.gov/clinicaltrials/developments/anti- 
angio-table). Some of these agents have unknown mechanisms of actions (e.g. 
Thalidomide) but have been shown to have anti-angiogenic properties in pre- 
clinical testing. More recently, some agents have been developed, which have 
multiple targets. For example, BIBF1120 (Boehringer Ingelheim) is an oral triple 
angiokinase inhibitor with activity against VEGFR, PDGFR, and FGFR.
Table 1.1 Anti-angiogenic agents in clinical trial
Drug Clinical stage Mechanism
Drugs that block matrix
breakdown
Dalteparin Phase 2/3 Heparin binding growth factor 
inhibitor
Suramin Phase 1/2 Heparin binding growth factor 
inhibitor
Drugs that directly inhibit
endothelial cells
ABT-510 Phase 1/2 Thrombospondin-1 mimetic
Lenalidomide Phase 3 Cytokine and immunomodulator
LY317615 Phase 2/3 Protein kinase C beta inhibitor
Thalidomide Phase 3 Cytokine and immunomodulator
Soy Isoflavone Phase 2 Soy protein isolate
Drugs that block activators
of angiogenesis
AMG-706 Phase 1/2 VEGFR1 PDGFR/Kit/Ret
Bevacizumab Phase 3 Monoclonal antibody to VEGF
AZD2171 Phase 2/3 VEGFR-1,2,3
Bay 43-9006 Phase 3 RAF/VEGFR/PDGFR
PI-88 Phase 2 Heparanase/VEGF/FGF-1,2
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PTK787/ZK 222584 Phase 1/2 VEGFR-1,2,3
SU11248 Phase 3 VEGFR/PDGFR/KIT/FLT3
XL 184 Phase 1 VEGFR-2/Met/KIT/FLT3/Tie-2
ZD6474 Phase 2/3 VEGFR-2/EGFR
BIBF1120 Phase 1/2 VEGFR/FGFR/PDGFR
VEGF trap Phase 2/3 VEGFR-1,2 fused to Fc lgG1
D rugs tha t in h ib it
endo the lia l ce ll func tion
ATN-161 Phase 1/2 avpi-integrin inhibitor
EMD-121974 Phase 1/2 avP3/a vp5-integrin inhibitor
Celecoxib Phase 2/3 COX-2 inhibitor
1.3.3 Small molecule vascular disrupting agents
1.3.3.1 Flavanoids
Flavone acetic acid (FAA) was originally developed as an anti-inflammatory drug 
and was found to have significant anti-vascular and anti-tumour activity in murine 
tumours (Corbett et al 1986, Kerr et al 1989). The toxicity and lack of anti-tumour 
activity in phase 1 and 2 clinical studies (Havlin et al 1991, Kaye et al 1990, Kerr 
at al 1989, Weiss et al 1988, Kerr et al 1987) led to the development of the active 
and more potent analogue, DMXAA (Antisoma) (Figure 1.3).
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Figure 1.3 The chemical structures of FAA (a), and DMXAA (b).
The exact mechanism of action of DMXAA is unknown but is thought to involve 
the production of a range of cytokines and anti-vascular agents (Baguley 2003). 
DMXAA may upregulate nuclear-factor Kp (NFk(3) gene transcription on vascular 
endothelial and tumour cells, leading to production of tumour necrosis factor and 
other cytokines (Karin et al 2000, Woon et al 2002). DMXAA has a direct effect 
on the tumour vascular endothelium causing DNA strand breaks and endothelial
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cell apoptosis, increase in permeability, platelet activation and release of 
serotonin (5HT), and a rapid decrease in blood flow (Lash et al 1998, Ching et al 
2002, Baguley et al 1997, Zwi et al 1994). This is followed by the production of 
tumour necrosis factor alpha (TNFa). which is crucial to the vascular disrupting 
activity, as well as toxicity of DMXAA (Baguley 2003). Indeed, the lack of anti­
tumour activity by FAA was thought to be due to a species-specific difference in 
the ability to induce TNFa, as FAA is unable to induce TNFa in human 
mononuclear cell lines in contrast to its activity in murine cell lines (Ching et al 
1994). Other cytokines and mediators implicated in the anti-vascular activity of 
DMXAA include interferon-y. mRNA for interferon-a, chemokine interferon- 
inducible protein-10, and nitric oxide (Pang et al 1998, Cao et al 2001). The anti­
tumour efficacy of DMXAA has been shown to be enhanced by radiation, 
cytotoxics, bioreductive agents, and immunomodulatory agents (Cliffe et al 1994, 
Pruijin et al 1997. Wilson et al 1998, Pedley et al 1996, Pedley et al 1999).
The effects of DMXAA on tumour perfusion were studied in animal tumour 
models. Using the 8oRbCI extraction technique, DMXAA was shown to cause a 
79% reduction in tumour perfusion, with no recovery even after 24 hours (Murata 
et al 2001). Reduction in blood flow after DMXAA was also shown to correspond 
to onset of hypoxia in the murine RIF-1 tumours, the MDAH-MCa-4 mouse 
mammary carcinomas, and in NZMN10 human melanoma xenografts (Siim et al 
2000). Using MRI, DMXAA treated FaDu and A253 xenografts showed a 78% 
and 49% reduction in vascular perfusion respectively. CD31-immunostaining of
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tumour sections revealed three-fold and two-fold reductions in microvessel 
density respectively 24 hours after treatment (Seshadri et al 2006). Similarly, MRI 
studies on the rat GH3 prolactinomas, showed a reduction in MR vascular 
parameters 24 hours after treatment with 350 mg/kg DMXAA. However, at 
200mg/kg, no changes in MR parameters were observed despite histological 
evidence of tumour necrosis and a significant increase in plasma 5- 
hydroxyindoleacetic acid (5-HIAA) (McPhail et al 2006).
Two phase-1 trials were conducted in parallel by Cancer Research UK in New 
Zealand and the UK. In the UK study, DMXAA was given weekly at doses 
ranging from 6 to 4900mg/m2 to 46 patients. The maximum tolerated dose was 
established at 3700mg/m2; dose-limiting toxicities in the form of urinary 
incontinence, visual disturbance, and anxiety were observed at the highest dose 
level (Rustin et al 2003). In the New Zealand study, a total of 63 patients 
received DMXAA every three weeks as a 20 minute infusion. Dose-limiting 
toxicities were observed at 4900mg/m2, including confusion, tremor, slurred 
speech, visual disturbance, anxiety, urinary incontinence and possible left 
ventricular failure. Transient prolongation of the corrected cardiac QT interval 
was seen in 13 patients evaluated at doses of 2000mg/m2 and above. A patient 
with metastatic cervical carcinoma achieved an unconfirmed partial response at 
1100mg/m2, progressing after eight courses (Jameson et al 2003). Patients from 
these two studies underwent MRI examinations, demonstrating reductions in MR 
vascular parameters across a wide range of dose levels (Galbraith et al 2002). A
further phase 1 study was carried out to identify the optimal dose of DMXAA for 
combination studies (McKeage et al 2006). Fifteen patients received weekly 
DMXAA at doses ranging from 300 to 3000mg/m2. The recommended dose was 
1200m/m2 because this dose produced no significant effect on heart rate- 
corrected cardiac QT interval, produced near maximum levels of 5-HIAA, 
achieved DMXAA plasma concentrations within the preclinical therapeutic range, 
and was well tolerated.
Phase 1 b/2 combination studies of DMXAA are underway. In two separate 
studies, patients with recurrent ovarian carcinomas and patients with advanced 
(stage IIIB and IV) non-small cell lung cancer respectively were randomised to 
receive carboplatin, and paclitaxel. with or without DMXAA. Preliminary data 
reported no significant additional toxicity with DMXAA, and encouraging early 
response rates (Gabra et al 2006, McKeage et al 2006).
1.3.3.2 Tubulin binding drugs
The mechanism of action of tubulin binding drugs has been extensively studied 
(Attard et al 2006). Microtubules are formed from the polymerisation of soluble 
tubulin heterodimers. They form the backbone of the cellular cytoskeleton, and 
have a wide range of cellular functions. They are involved in the transport of 
organelles, transmitters and receptors down neuronal axons. They form mitotic 
spindles that transport daughter chromosomes to separate poles of the dividing 
cell during mitosis. Drugs that interfere with microtubule function cause mitotic
arrest leading to ceiiular apoptosis, which is thought to be the primary anti­
neoplastic action of tubulin binding drugs. Examples of tubulin binding drugs are 
commonly used chemotherapeutic agents like the vinca alkaloids (vincristine, 
vinblastine etc.), and the taxanes (paclitaxel, docetaxel etc.).
Early studies with the tubulin-binding, anti-inflammatory drug colchicine 
demonstrated that it induces haemorrhagic necrosis in tumours by damaging the 
tumour vasculature (Ludford 1945, Ludford 1948) (Figure 1.4).
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Figure 1.4 The chemical structure of colchicine.
Clinical studies confirmed the vascular disrupting activity of colchicine but only at 
toxic and potentially lethal doses (Seed 1940). Similarly, the vinca alkaloids have 
been shown to have anti-vascular activity but only at doses close to their
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maximum tolerated dose (MTD) (Baguley et al 1991, Hill et al 1993, Hill et al 
1994). Newer agents have since been developed, that can induce vascular 
damage in tumours at doses much lower than the MTD. These novel tubulin 
binding agents work by acting near the colchicine binding site of the p-subunit of 
endothelial cell tubulin, resulting in depolymerisation of microtubules and 
disorganisation of actin and tubulin, leading to changes in the three-dimensional 
shape of newly formed endothelial cells. These cells are particularly sensitive to 
the effects of tubulin binding agents because they lack a well developed actin 
cytoskeleton and pericytic infiltration that can help maintain its shape. The 
rounding-up of the shape of endothelial cells can cause an increase in vascular 
resistance, as well as a rapid increase in vascular permeability. The tumour 
microcirculation already possesses a high interstitial fluid pressure, and the 
leakage of plasma proteins into the extracellular space can further exacerbate 
the interstitial pressure, leading to vascular collapse. The loss of fluid from the 
vascular space can also cause an increase in haematocrit and consequently 
increase viscous resistance to blood flow. Exposure of the basement membrane 
to flowing blood can also initiate the coagulation cascade leading to thrombus 
formation and reduction in tumour blood flow (Tozer et al 2005) (Figure 1.5).
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Figure 1.5 Tubulin binding agents bind to tumour endothelial cell tubulin 
(a), resulting in depolymerisation of microtubules, leading to 
rounding up of the shape of endothelial cells (b). This causes 
an increase in vascular resistance, permeability, and 
interstitial fluid pressure, resulting in vascular collapse (c). 
This can lead to blood cell rouleaux formation, activation of 
the coagulation cascade, thrombus formation, and tumour 
haemorrhagic necrosis (d). (Reproduced from Siemann 2002).
1.3.3.2.1 CA4P
CA4P (OxiGene) is the first small molecule tubulin binding agent that displays 
potent and selective toxicity towards tumour vasculature below its MTD (Figure 
1 .6 ).
Figure 1.6 The chemical structure of CA4.
CA4P is a synthetic, water soluble, phosphorylated prodrug of the natural product 
combretastatin A4 (CA4), which was originally isolated from the bark of the 
African bush willow, Combretum caffrum. In vitro, the parent CA4 is a strong 
tubulin-binding agent that has potent activity in preventing tubulin polymerisation 
and microtubule assembly. Although the exact mechanism for the anti-vascular 
effects of CA4P remains under investigation, preclinical evidence suggests that it 
may be a consequence of endothelial cell shape changes and cell damage.
H
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In experimental tumours, CA4P activates the Rho/Rho-kinase pathway, causing 
microtubule depolymerisation and remodelling of the actin cytoskeleton, resulting 
in an acute change in endothelial cell shape, and acute increase in vascular 
permeability (Tozer et al 2005, Kanthou and Tozer 2002, Tozer et al 2001, 
Galbraith et al 2001). CA4P disrupts the molecular engagement of the 
endothelial cell-specific junctional molecule vascular endothelial-cadherin (VE- 
cadherin) in vitro and in vivo in mice, leading to increase in vascular permeability 
(Vincent et al 2005). The increase in tumour vascular permeability can result in 
leakage of plasma proteins into the extracellular space. This causes a further 
increase in the high interstitial fluid pressure, which results in vascular collapse. 
Indeed, tumours which are more permeable appear to be more susceptible to the 
vascular shutdown caused by CA4P (Beauregard et al 2001).The loss of fluid 
from the vascular space can also cause an increase in haematocrit and 
consequently increase viscous resistance to blood flow. The reduction in blood 
flow by CA4P has also been shown to be enhanced by nitric oxide synthase 
inhibition, suggesting that nitric oxide is involved in the mechanism of action of 
CA4P (Parkins et al 2000. Davis et al 2002).
In pre-clinical studies, CA4P induces an acute vascular shutdown at less than 
10% of the MTD (Dark et al 1997). Using the 86RbCI extraction technique, a 50- 
60% reduction in tumour perfusion was observed in tumours after a single intra- 
peritoneal administration of lOOmg/kg of CA4P, which was associated with a 
greater than 90% loss of functional vascular volume within six hours post­
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treatment (Chaplin et al 1999). Similar findings have been demonstrated in the 
murine adenocarcinoma CaNT using Hoeschst 33342 dye (Chaplin and Hill
2002 ).
Vascular changes after CA4P in animal tumour models have also been studied 
using functional imaging. DCE-MRI and spectroscopy (MRS) were used to 
demonstrate reductions in perfusion at the central regions of the tumour after 
CA4P which corresponded to haemorrhagic necrosis seen on histological section 
(Beauregard et al 1998). Using DCE-MRI, tumour perfusion in rodent tumours 
were measured after receiving CA4P (30mg/kg), and showed significant 
decreases at 90 minutes. Twenty-four hours after CA4P, the centre of the tumour 
remained necrotic while there was re-perfusion at the rim of the tumour to 
baseline levels suggesting that CA4P selectively targets the necrotic cells in the 
tumour centre (Zhao et al 2005). This rim of surviving cells is thought to be a 
consequence of the shared normal vessel circulation between the perimeter of 
tumours and neighbouring normal tissue. More recently, it was demonstrated that 
the viable tumour rim might be the result of circulating endothelial progenitor cells 
which home to the rim following CA4P treatment (Shaked et al 2006).
Phase I human studies of CA4P used weekly for three weeks with a one week 
break have been completed (Rustin et al 2003). CA4P was rapidly 
dephosphorylated to the active compound, which was further metabolised to the 
glucuronide. The only toxicity that possibly was related to the drug dose up to
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40mg/m2 was tumour pain. Dose-limiting toxicity (DLT) was reversible ataxia in 
two patients treated at 114mg/m2, and vasovagal syncope and motor neuropathy 
in two patients treated at 88mg/m2. One patient suffered fatal ischemia in 
previously irradiated bowel at 52mg/m2. Other drug-related grade 2 or higher 
toxicities seen in more than one patient were pain, lymphopaenia, fatigue, 
anaemia, diarrhoea, hypertension, hypotension, vomiting, visual disturbance, and 
dyspnoea.
A separate phase 1 study looking at the cardiovascular safety profile of CA4P 
reported significant increases in corrected QT intervals (QTc) on 12-lead 
electrocardiogram (ECG) at three and four hours after administering CA4P 
(Cooney et al 2004). Two patients also had ECG changes consistent with acute 
coronary syndrome within 24 hours of CA4P infusion. Preliminary report from a 
subsequent study has shown that the increase in QTc was transient, with partial 
recovery by six hours after CA4P (Ng et al 2005). However, it is now 
recommended that patients receiving CA4P should not have significant cardiac 
medical history or prolonged QTc at baseline.
Functional imaging studies were incorporated into the phase 1 trials to evaluate 
the tumour vascular effects of CA4P. Using DCE MRI, Galbraith et al (2003) 
showed that CA4P caused significant reductions in tumour Ktrans in six of 16 
patients treated at 46.8mg/m2, with a significant group mean reduction of 37% at 
4 hours after treatment, with partial recovery by 24hours. The mean reduction in
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tumour initial area under the gadolinium-diethylenetriamine pentaacetic acid 
concentration-time curve (AUC) was 33% at 4 hours, again with some recovery 
by 24 hours demonstrating a transient vascular shutdown. No significant 
reductions in DCE-MRI vascular parameters were seen in muscle or in kidney. 
Visual inspection of tumour perfusion parameter maps provided preliminary 
evidence for the selective targeting of CA4P to the central region of the tumour. A 
further 13 patients on this study were scanned using H21bO PET and CVjO PET 
(Anderson et al 2003); reductions of 49% and 15% were seen in tumour 
perfusion and blood volume respectively 30 minutes after CA4P administration. 
Again, there was limited recovery of tumour blood volume and perfusion by 24 
hours. Vascular changes were also observed in spleen and kidney at 30 minutes 
after CA4P, with recovery by 24hours.
1.3.3.2.1.1 Combination therapy with CA4P
CA4P appears to selectively disrupt the vasculature in the tumour centre 
resulting in haemorrhagic necrosis, while leaving a rim of viable tumour cells at 
the periphery that can re-vascularise and proliferate. The partial recovery in 
tumour vascularity after single agent CA4P, and the lack of objective response in 
phase I human studies strongly suggests that in order to optimise the therapeutic 
effects of CA4P, it needs to be combined with another treatment modality that 
can target the surviving tumour rim. This viable rim is vascularised and well 
oxygenated and is likely to be in a state of rapid proliferation, thus lending itself 
well to tumour cell killing by conventional therapies.
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CA4P has been shown to enhance the tumour cytotoxic effects of conventional 
chemotherapeutic agents. Tumour growth was impeded when CA4P was 
combined with 5-fluorouracil in experimental murine colon adenocarcinoma 
(Grosios et al 2000). In the resistant medullary thyroid carcinoma model in mice, 
the combination of CA4P and doxorubicin extended the tumour doubling time 
compared to untreated controls (Nelkin and Ball 2001). CA4P when combined 
with cisplatin caused increased tumour cell death secondary to haemorrhagic 
necrosis in rodent (KHT sarcoma), human breast (SKBR3) and ovarian (OW-1) 
tumour models (Siemann et al 2002). In a xenograft model of Kaposi's sarcoma 
grown in athymic mice, significant tumour growth delay was achieved when 
CA4P was combined with cisplatin (Li et al 2002). CA4P when combined with 
irinotecan also significantly increased the tumour volume doubling time in the 
experimental rhabdomyosarcoma tumour model in rats (Wildiers et al 2004).
CA4P in combination with other novel agents has also been studied. Using the 
SW1222 colorectal xenografts, antibody-targeted radioimmunotherapy was 
shown to be more effective against the well perfused tumour rim but was less 
effective at the more hypoxic centre, producing tumour regressions for 
approximately 35 days. When 131 l-labeled anti-carcinoembryonic antigen IgG, 
was combined with CA4P, complete cures were obtained (Pedley et al 2001). 
The spatial distribution of this combination was also studied and revealed that 
radioimmunotherapy effectively treated the tumour rim only, while CA4P targeted
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the tumour centre (Pedley et al 2002). More recently, it was demonstrated that 
treatment of tumour-bearing mice with CA4P leads to an acute mobilisation of 
circulating endothelial progenitor cells (CEP), which home to the viable tumour 
rim. Disruption of this CEP spike by anti-angiogenic drugs resulted in marked 
reductions in tumour rim size and blood flow as well as enhanced anti-tumour 
activity (Shaked et al 2006).
CA4P has been shown to enhance or act synergistically with radiation (Siemann 
and Horsman 2002, Li et al 1998, Murata et al 2001). Radiotherapy is known to 
be effective at the tumour rim where blood flow and oxygenation is relatively 
normal (Steel 1983). In addition, a high oxygen tension relative to the more 
hypoxic tumour core lends itself well to radiation treatment where tumour 
damaging free radical formation is largely oxygen dependent. Ionising radiation 
treatment targets the richly oxygenated areas of tumours, whereas the more 
hypoxic inner region of tumours frequently remains relatively unaffected and will 
continue to survive and grow. Thus, combining CA4P with radiotherapy might 
provide the potential synergy that is required to treat the whole tumour.
Pre-clinical studies have demonstrated synergy between CA4P and radiation. In 
nude mice bearing the murine adenocarcinoma CaNT, CA4P was combined with 
a fractionated radiation schedule, and demonstrated a 63% increase in tumour 
regression compared to radiation alone. Furthermore, 50% of the tumour bearing 
animals achieved a complete response, which was not observed with radiation or
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CA4P alone (Chaplin et al 1999). In both the KHT sarcoma and the C3H 
mammary carcinoma in mice, CA4P combined with radiation caused an increase 
in tumour necrosis (Murata 2001). In the rat rhabdomyosarcoma model, CA4P 
significantly enhanced the growth delay effects of ionising radiation, with the 
greatest effects being seen with large tumours (Landuyt et al 2001). In KHT 
sarcoma-bearing mice, CA4P administered after radiation treatment significantly 
reduced tumour cell survival compared to radiation alone (Li et al 1998).
The possibility that CA4P might affect radiation damage in normal tissue was 
assessed by Murata et al (2001) using mouse normal foot skin, a well 
established sensitive endpoint representative of acute morbidity. The results 
showed that CA4P given 30 minutes post irradiation significantly improved 
tumour response to radiation as evidenced by the increased induction of tumour 
necrosis but did not enhance radiation-induced skin damage. These observations 
suggest that CA4P preferentially targets the tumour vasculature and that the 
enhancement of radiation damage in tumours is associated with such vascular 
changes.
The apparent concern in such combination studies is the potential induction of 
hypoxia by CA4P rendering the tumour radioresistant, and the effects of vascular 
shutdown hindering delivery of systemic cytotoxic drugs to the tumour. In the 
C3H mammary carcinoma, tumour hypoxia measured with the Eppendorf oxygen 
electrode increased within one hour of CA4P, and was sustained up to six hours,
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with partial recovery at 12 and 24 hours (Horsman et al 1998). More recently, it 
was shown using 19F MRI oximetry and DCE-MRI that CA4P induces hypoxia 
and reduced perfusion in the syngeneic 13762NF rat breast carcinoma within 90 
minutes of treatment (Zhao et al 2005). The initial changes in oxygenation in the 
tumour centre and periphery were parallel but by 24 hours, there was significant 
re-perfusion and re-oxygenation at the periphery of the tumour, while the centre 
remained hypoxic. The spatial and temporal effects of CA4P might therefore 
explain the dependence of timing and scheduling of the anti-tumour activity of 
CA4P when combined with radiotherapy and chemotherapy. In the C3FI 
mammary carcinoma, improvement in tumour control was only observed when 
CA4P was administered at the same time or after radiation (Murata et al 2001, 
Horsman and Murata 2002). In a variety of tumour models, tumour cell death 
was significantly enhanced without increase in bone marrow toxicity when CA4P 
was administered one to three hours after cisplatin but not when it was given one 
hour before cisplatin (Siemann et al 2002). In contrast, the combination of 
irinotecan and CA4P did not appear to be affected by scheduling in causing 
tumour growth delay in the rhabdomyosarcoma tumour model in WAG/Rij rats 
(Wildiers et al 2004).
The importance of scheduling was demonstrated in a phase 1 dose-escalating 
combination study of CA4P and carboplatin (Bilenker et al 2005). In this study, 
CA4P was administered one hour after carboplatin on a 21 day treatment cycle 
and failed to reach therapeutic doses of either CA4P or carboplatin because of
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dose-limiting thrombocytopaenia. Pharmacokinetic interaction between the two 
drugs was suggested to be the reason for the greater exposure of carboplatin (as 
area under the curve) causing increased thrombocytopaenia. Also, CA4P has 
previously been shown using H2150  PET to transiently reduce kidney perfusion in 
patients, with full recovery by 24 hours (Anderson et al 2003). Therefore, CA4P 
when administered one hour after carboplatin, might have affected renal 
excretion of carboplatin and increased its toxic side effects. A similar study 
combining CA4P with paclitaxel, carboplatin, or both is ongoing (Rustin et al 
2005). In this study, CA4P was administered to patients 18 to 22 hours prior to 
receiving chemotherapy. Preliminary results reported that dose escalation 
reached therapeutic levels of CA4P and both cytotoxic agents without 
enhancement of chemotherapy related toxicity.
The rationale for combination therapy with CA4P therefore stems from their 
different and potentially complementary mechanisms and site of action and their 
non-overlapping toxicity profiles. Careful timing and sequencing of these agents 
is critical to treatment success. Presently, early phase clinical trials of CA4P in 
combination with radiotherapy, chemotherapy, immunotherapy, and anti- 
angiogenic agents are underway.
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1.3.3.2.2 Oxi-4503
Oxi-4503 (OxiGene) is the diphosphate prodrug form of combretastatin A1 which 
has been reported to have more potent anti-vascular and anti-tumour effects than 
CA4P (Figure 1.7).
Figure 1.7 The chemical structure of Oxi-4503.
In murine breast adenocarcinoma CaNT, Oxi4503 at a dose of 1 mg/kg induced 
a greater than 50% reduction in functional vascular volume, which increased to 
80% or more following doses of 10, 25 and 50 mg/kg. In contrast, CA4P induced 
approximately 40% vascular shutdown at 50 mg/kg, but had no measurable 
effect at 10 mg/kg. In addition, Oxi4503 but not CA4P induced significant tumour 
growth retardation at comparable doses (Hill et al 2002). Similar reductions in 
blood flow measured using intravenous injections of fluorescence beads, and 
tumour growth were observed in mice tumours after Oxi4503. In this study, the 
spatial heterogeneity in tumour blood flow was studied using quantitative 
fluorescence microscopy, and showed that Oxi4503 had greater vascular
0
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disrupting effects at the tumour periphery than CA4P, where only central regions 
were affected (Hua et al 2003). The additional potency of Oxi4503 compared to 
CA4P, may be due to the rate of dephosphorylation, or the production of a 
quinine metabolite with enhanced cytotoxic activity (Thorpe et al 2003). Oxi4503 
is currently in phase 1 clinical trials.
1.3.3.2.3 AVE8062 (formerly AC7700)
AVE8062 (Aventis) is a synthetic water soluble combretastatin A4 derivative, that 
has been shown in animal tumour models to have potent anti-vascular and anti­
tumour activity (Hori et al 1999, Hori et al 2002). The mechanisms of action of 
AVE8062 was evaluated using intravital microscopy, which showed that 
AVE8062 induced a powerful and long-lasting constriction of host arterioles, so 
that complete stasis of blood flow occurred in downstream vessels, which 
supplied blood to tumours, resulting in complete vascular thrombosis (Hori et al
2003). Preliminary results from a phase 1 clinical trial of AVE8062 administered 
once weekly for 3 weeks every 28 days, reported asymptomatic systolic 
hypotension in patients. A change in DCE-MRI vascular parameters was also 
observed (Tolcher et al 2003).
1.3.3.2.4 ZD6126
ZD6126 (Astra Zeneca) is a phosphate prodrug of the tubulin binding agent 
ZD6126 phenol (N-acetylcolchinol) (Figure 1.8).
Figure 1.8 The chemical structure of ZD6126.
In vivo studies of ZD6126 were carried out in a range of tumour models, and 
showed that at doses 8 to 16 times lower than the MTD, ZD6126 causes 
vascular shutdown leading to extensive tumour necrosis, and was able to 
achieve growth delay in certain tumours (Blakley et al 2002). Similar findings 
were observed in the CH3 mouse mammary carcinoma where ZD6126 induced a 
significant decrease in tumour perfusion and oxygenation, and a significantly 
increased necrotic fraction (Horsman and Murata 2003). Functional imaging 
studies using MR studies were also performed to assess the vascular effects of 
ZD6126. In the rat GH3 prolactinomas and murine RIF-1 fibrosarcomas a dose- 
dependent decrease in MR vascular parameters was observed after ZD6126 
(Robinson et al 2003). In the GH3 prolactinoma, 50 mg/kg of ZD6126 resulted in 
a decrease in MR vascular parameters, with no recovery of perfusion even at 96 
hours (McIntyre et al 2004). ZD6126 has also been shown to enhance the 
therapeutic effects of chemotherapy, radiotherapy, and anti-angiogenic agents
(Siemman and Rojiani 2002, Siemman and Rojiani 2002, Horsman and Murata 
2003, Raben et al 2004, Cionini et al 2004).
In clinical studies, the tumour anti-vascular activity of ZD6126 was demonstrated 
using DCE-MRI. In 9 patients, at doses of 80mg/m2 and higher, MR vascular 
parameters after ZD6126 treatment were reduced to 36-72% of the baseline 
values (Evelhoch et al 2004). Preliminary data from a phase 1 dose-escalating 
study of ZD6126 on a 21 day cycle was reported, with one patient experiencing 
grade 2 ischaemic changes on 12-lead electrocardiogram (EGG) and grade 3 
elevation in troponin I with subsequent demonstration of coronary artery disease 
(Gadgeel et al 2002). A completed phase 1 study with 32 patients receiving 
weekly ZD6126 (Beerepoot et al 2006), also reported a patient with a history of 
ischaemic heart disease developing acute myocardial infarction two weeks after 
drug discontinuation. Dose limiting toxicities were hypoxia caused by pulmonary 
embolism and an asymptomatic decrease in left ventricular ejection fraction at 28 
mg/m2. In this study, circulating endothelial cells, which were measured as a 
pharmacodynamic marker of vascular damage, were shown to increase after 
infusion of ZD6126.
1.4 Functional imaging of tumour vasculature
Over the next few years, an increasing number of vascular targeting drugs will be 
used in the treatment of patients with cancer, which in turn will increase demand
for non-invasive methods of assessing tumour vascularity in vivo. There are 
several reasons for this. First, these drugs may not alter tumour size as a 
consequence of their action; thus, conventional criteria for therapeutic response 
assessment, based on tumour size change, may be inappropriate (World Health 
Organisation 1979, Therasse et al 2000, Kerbel and Folkman 2000). Second, 
functional imaging can provide pharmacodynamic information related to drug 
mechanism of action which, in early clinical trials of new therapeutic agents can 
support the decision to go ahead and develop larger phase 3 clinical studies with 
clinically relevant end-points. Third, vascular targeting drugs tend to have a wider 
therapeutic window than conventional drugs. Thus, in early-phase dose-finding 
trials, relying solely on toxicity-based criteria to define a dose has been 
suboptimal. Biologic changes, assessed by these imaging methods, can be used 
to show proof of principle of drug activity, and a lower dose than defined using 
toxicity-based criteria may be selected for further study. Finally, functional 
imaging techniques may have an advantage over the current standard of 
quantification in histological studies of angiogenesis using microvessel density 
counting, which is invasive and limited by random sampling errors and observer 
variability.
Several imaging modalities can assess the vascular function of human tumours. 
Apart from cost and logistics issues, the choice of modality will depend on our 
understanding of both the drug mechanism and the capabilities and limitations of 
the imaging technique. Perfusion CT (also known as dynamic contrast enhanced
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CT), dynamic contrast enhanced magnetic resonance imaging (DCE-MRI), and 
positron emission tomography (PET) are the imaging techniques most commonly 
used in the clinical evaluation of vascular targeting drugs.
1.4.1 PET
Positron emission tomography (PET) can be used to quantify tumour 
physiological characteristics such as glucose metabolism, blood flow and blood 
volume, which are relevant to tumour angiogenesis and its therapy (Laking and 
Price 2003). Proton rich isotopes act as PET radiotracers that decay by positron 
(positively charged electron) emission. When its kinetic energy is dispersed, the 
positron combines with a normal electron and the two particles are annihilated. 
They are converted to two gamma ray photons of equal energy which are emitted 
180 degrees apart, and are detected coincidentally with a PET camera, which is 
a ring-shaped array comprising a large number of scintillation detectors. When 
two scintillation detectors, separated 180 degrees apart are stimulated 
simultaneously, they will transmit a coincident signal. Using tomographic 
reconstruction algorithms, the spatiotemporal distribution of the positron emitter 
can be localised three-dimensionally.
PET with [18F]-fluorodeoxyglucose (18FDG), has been advocated as a tool to 
monitor clinical and sub-clinical responses after cancer treatment (Young et al 
1999). In most malignant tissues, there is increased cellular uptake and 
accumulation of phosphorylated FDG by hexokinase. FDG-6-phosphate is not
metabolised intracellularly due to the position of the 18F label and is therefore 
biochemically trapped. Measuring the uptake of FDG serves as a proxy for 
glucose metabolism. 18FDG PET has been shown to be superior to conventional 
response criteria using CT in monitoring response to imatinib therapy in patients 
with gastrointestinal stromal tumours (Antoch et al 2004). 18FDG PET is also 
widely used in the diagnosis, prognostication and therapeutic monitoring of a 
wide variety of cancers (Weber 2005). Agents that deprive tumours of blood 
supply also impact metabolism and their therapeutic efficacy are therefore 
potentially measurable using FDG-PET. 1sO-labeled water (H2150 ) is freely 
diffusible into and out of tissue water, is biologically and metabolically inert, and 
can be used to measure tissue perfusion. 150-labeled carbon monoxide (C150 ) 
binds irreversibly with haemoglobin to form C 150-H b carboxyhaemoglobin, which 
stays within the vascular space and can be used to measure vascular blood 
volume. Fl2150  and C1sO PET have been used to assess tumour vascular 
response following CA4P in a phase 1 clinical trial (Anderson et al 2003). 
Hypoxia imaging is also possible using tracers that are trapped within cells in the 
reduced state (Krause et al 2006). 18F-fluromisonidazole (18F-MISO) has a high 
accumulation in hypoxic tissue that is proportional to the hypoxic fraction of the 
tumour. 18F-MISO has been used to measure hypoxia in human cancers 
including lung, head and neck, renal, brain and rectal tumours, and has been 
used to monitor the effects of cancer therapy (Krause et al 2006). Copper Cu- 
60,-62,-64 labelled methylthiosemicarbazone (Cu-ATSM) has also been 
developed for hypoxic imaging. ATSM compounds are freely diffusible, and are
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rapidly taken up by hypoxic cells but are quickly washed out of normoxic cells, 
and have the potential advantage of a more rapid visualisation of hypoxia signal. 
Patients with lung cancer were investigated with (60Cu) ATSM PET prior to 
receiving therapy (chemotherapy only, radiotherapy only or chemo-radiotherapy). 
Non-responders were shown to have a significantly higher (60Cu) ATSM uptake 
than in responders (Dehdashti et al 2003). Tracers have also been used to label 
specific organic compounds in the angiogenic pathway, such as VEGF, 
potentially allowing for the direct imaging of tumour angiogenesis (Li et al 2001). 
The major limitations of PET are relatively poor spatial resolution, limited clinical 
availability, high radiation dose and the expense in using and logistical difficulty 
in producing short-lived isotopes.
1.4.2 DCE-MRI
DCE-MRI is relatively well established in imaging angiogenesis (Padhani 2003). 
It does not employ ionising radiation, therefore allowing repeated examinations, 
and this is particularly suited to early phase dose finding trials. DCE-MRI 
measurements of tumour perfusion have also been correlated against 
histological markers of angiogenesis in a variety of tumours (Buckley et al 1997, 
Hawighorst et al 1997). DCE-MRI is essentially a single level technique although 
multiple slices can be examined. DCE-MRI measures the change in signal 
intensity over a period of time as the contrast agent passes through the tumour 
vasculature. It is able to distinguish between malignant and benign tissues 
because their vasculature is morphologically and functionally different. A
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significant disadvantage of MRI is that the relationship between MR signal 
intensity change and contrast agent concentration, particularly for large vessels, 
is not easily defined. The signal intensity is dependent on multiple factors 
including the tissue T1 relaxation time, contrast agent dose, rate of injection, the 
chosen imaging sequence and parameters.
Vascular parameters may be evaluated by two MR sequences. T1 weighted 
sequences reflect microvessel perfusion, permeability and extracellular leakage 
space. T2* weighted sequences reflect tissue perfusion and blood volume. In T1 
sequences, the change in the signal intensity of the commonly used 
paramagnetic contrast agent, gadolinium-diethylenetriamine pentaacetic acid 
(Gd-DTPA), measured over several minutes can be analysed using 
pharmacokinetic models. Gd-DTPA is neither freely diffusible nor a pure blood 
pool agent, and therefore the transfer constant (Ktrans) of Gd-DTPA from the 
plasma into the extracellular space will be affected by permeability changes as 
well as perfusion changes. In extra-cranial tumours, due to high microvessel 
permeability, blood perfusion will be the dominant factor and Ktrans 
approximates to the blood flow per unit volume of tissue. Other vascular 
parameters measurable using T1 weighted sequences are the extracellular 
leakage space (ve), and the rate of contrast return into the vasculature (kep) 
(Figure 1.9). T2* weighted sequences monitor the passage of contrast through 
the vascular space, and the loss of signal intensity is dependent on the vascular 
concentration of the contrast agent, and microvessel size and density. Kinetic
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modelling of the signal intensity change allows the relative quantification of blood 
volume (rBV), mean transit time (MTT), and blood flow (rBF).
Hypoxic imaging with MR is possible with blood oxygen level dependent (BOLD) 
MRI, which uses endogenous deoxyhaemoglobin as the source of contrast. 
Deoxyhaemoglobin increases the MR transverse relaxation rate R2* (=1/T2*) of 
water in blood and in the surrounding tissue, therefore acting as an intrinsic 
contrast agent. Deoxyhaemoglobin concentration changes with oxygen content 
but it is also affected by tissue perfusion. The major advantage of BOLD MRI is 
that there is no need to administer contrast material, and therefore it can be 
repeated as needed.
1.4.3 Perfusion CT
Perfusion CT allows direct quantification of vascular function, as there is a direct 
linear relationship between enhancement change and iodine concentration. For 
example, at 80kV, 1 mg/ml iodine is equivalent to a Hounsfield Unit (HU) change 
of 43HU. This is a significant advantage over DCE-MRI where the relationship 
between MR signal intensity change and contrast agent concentration is complex. 
Perfusion CT assessment of tumour vascularity is possible by tracking the 
temporal changes in tissue attenuation, as intravenously administered low 
molecular weight (<1kD) iodinated contrast media travels by blood flow to the 
tissue, and by rapid diffusion, leaks out from the vascular space into the 
extravascular space. To date, different image acquisition protocols, image
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analysis methods, and a variety of pharmacokinetic models exist for the 
quantification of physiologically based vascular parameters (Miles 2003, Dawson 
2006). In general, a non-contrast enhanced baseline image is acquired, followed 
by a series of repeated images after intravenous contrast medium administration. 
There is an initial vascular phase when the contrast media remains transiently in 
the intravascular space. During this first pass, contrast enhancement reflects 
tissue perfusion (blood flow per unit volume or mass of tissue) and blood volume. 
A typical scanning protocol would involve acquisition of up to 60 images, at a 
frequency of one image every second. Delayed phase studies are performed 
when the contrast agent passes through into the extravascular space. Delayed 
enhancement is determined by the rate constant of the transfer of contrast media 
into the extravascular space (transfer constant, K). K is a function of both tissue 
blood flow and the permeability surface product (PS); the latter is defined as the 
product of permeability and the total surface area of capillary endothelium in a 
unit mass of tissue. Whether K is dominated by flow or PS may be altered 
according to the experimental conditions. Delayed phase studies allow larger 
volumes to be covered, and images are obtained at a lower frequency but over a 
longer period (Figure 1.9).
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Contrast agent
Figure 1.9
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A simple two compartmental model valid for both CT and MRI. 
During the first pass, the contrast agent is transiently confined 
to the intravascular space. In the delayed phase, the contrast 
agent passes through into the extravascular space by simple 
diffusion (K or Ktrans), which is gradually balanced by the rate 
it is transferred back into the intravascular space (K2 or Kep).
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The limitations of perfusion CT include radiation exposure, the need for 
intravenous injections of contrast media, and the risk of hypersensitivity reactions. 
Perfusion CT measurements, like MRI, are also currently limited to a single axial 
level, limiting tumour coverage in heterogeneous tumours. Perfusion CT has 
several advantages over DCE-MRI in imaging the tumour vasculature. As 
mentioned previously, the reliable linear relationship between enhancement, 
measured as HU, and contrast concentration, allows straightforward 
quantification, compared to MR where quantification remains problematic. CT is 
widely accessible, relative cost effective, and commercial perfusion software is 
now available, and can be easily incorporated into existing CT protocols for day- 
to-day oncological imaging. There are also anatomical regions where CT is 
preferable to MR, for example the lung, where respiratory motion can produce 
artefacts that would interfere with MR evaluation. The introduction of multi­
detector CT (MDCT) has stimulated further interest in perfusion CT techniques. 
Unlike single detector CT, where the image slice position has to be determined 
prior to scanning, MDCT allows the CT scanner to acquire more than one slice 
simultaneously (Figure 1.10). The advantages of MDCT are improved spatial 
resolution, reduced scanning time, and the ability to scan a larger tissue volume. 
The use of perfusion CT to obtain tumour vascular measurements will be further 
described in Chapter 2.
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Figure 1.10 Multi-detector CT (MDCT) allows improved spatial resolution, 
faster scanning time, and the ability to acquire a larger volume 
(a), compared to single-detector CT where the image slice 
position has to be determined prior to scanning (b). (Images 
adapted from www.ctisus.org)
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1.5 Aim
There are three main objectives to this work. The first is to develop a repeatable 
clinical perfusion CT method that will allow quantification of tumour vascularity in 
whole tumours. The second is to assess the vascular changes that occur after 
treatment with fractionated radiotherapy alone and in combination with the 
vascular disrupting agent CA4P. The final objective is to measure the vascular 
changes that occur after treatment with the NOS inhibitor L-NNA.
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CHAPTER 2
VOLUMETRIC PERFUSION COMPUTED TOMOGRAPHY 
2.1. Introduction
Perfusion CT (also known as dynamic contrast enhanced CT) provides a 
quantitative and non-invasive method for studying tumour vascular function. CT 
is widely available and perfusion CT has been used increasingly as a clinical tool 
for monitoring responses to treatment with vascular targeting drugs (Thomas et 
al 2003, Xiong et al 2004, Willett et al 2004). It has been validated against a 
variety of techniques including microspheres, xenon CT and 150  labelled-H20 
PET (Gobbel et al 1991, Gobel et al 1993, Cenic et al 1999, Gillard et al 2000, 
Wintermark et al 2001, Purdie et al 2001) and has been correlated against 
histological markers of angiogenesis (Jinzaki et al 2000, Tateishi et al 2002, Yi et 
al 2004, Wang et al 2006). Up to now, CT assessment of tumour vascular 
parameters has been limited to a single tumour level, though a number of 
contiguous axial images at the same tumour level can be acquired with multi­
detector row scanners, depending on the row configuration. For example, with a 
16-detector row scanner, a z-axis coverage up to 24mm is possible, and with a 
64-detector scanner, a maximum coverage of 4cm is achievable.
However, it is well recognised that tumour vasculature exhibits spatial 
heterogeneity; blood flow can vary in different locations within a single tumour
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depending on the tumour microenvironment (Chaplin et al 1995, Kimura et al 
1996). Therefore, single level measurements of tumour vascularity will only 
provide a limited sample of the entire region of interest and may be 
unrepresentative of the tumour as a whole, especially in larger tumours. Greater 
tumour coverage has the potential to compensate for this heterogeneity, and 
hence to reduce measurement variability. In collaboration with Siemens Medical 
Solutions (Forchheim, Germany), a CT technique was developed that allows 
evaluation of tumour vascularity in entire tumour volumes.
2.2 Volumetric perfusion CT methodology
2.2.1 Image acquisition
Patients were scanned using a 16-detector row CT scanner (Sensation 16, 
Siemens Medical Solutions, Forchheim, Germany) (Figure 2.1). No additional 
patient preparation was required over and above that for a routine thoracic CT 
examination. An 18-gauge cannula was placed into an antecubital fossa vein 
while the patient lay supine on the scanner table. The majority of patients 
recruited into this study had lung cancer, and in order to minimise movement, all 
patients were carefully instructed on the correct breath-holding technique prior to 
scanning, and were allowed to practise several times. All scans were performed 
using breath-hold at tidal expiratory volume, as a consistent tumour position and 
coverage were more achievable in expiration than inspiration in our patient group.
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There was also direct communication between the patients and the radiographer 
at all times during scanning using a microphone and speaker.
Figure 2.1 The 16-detector row computed tomography (CT) scanner used 
in this research study
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An initial non-contrast breath-hold helical scan was performed ensuring that the 
entire lung tumour was encompassed, using the following imaging parameters: 
80kV, 120mAs, table feed 30mm, rotation time 0.5seconds, detector width 
1.5mm, reconstruction width 2mm, field of view 500mm, matrix 512mm. This 
non-contrast scan provided baseline images, and was used to plan the 
subsequent perfusion study. The level of the aortic arch was identified from these 
scans. A single axial scan was performed at the level of the aortic arch, to allow a 
region of interest (ROI) to be placed within the aorta for a subsequent contrast 
medium bolus tracking scan (CARE bolus, Siemens Medical Solution, Forchheim, 
Germany). Contrast of 108ml iobitridol 300mg iodine/ml (Xenetix 300, Guerbet, 
Paris, France) was administered using a dual headed pump injector (Injekttron 
CT2, Medtron, Saarbrucken, Germany), with a decreasing bolus infusion (32ml at 
4 ml/s for 8  seconds, 16mls at 2ml/s for 8  seconds, and 60mls at 1ml/s for 60 
seconds), and followed by a saline flush (20mls at 1ml/s for 20 seconds). The 
rationale for the multi-phasic contrast infusion protocol was to optimise 
experimental conditions for subsequent quantitative analysis of vascularity using 
Patlak based analysis (Patlak et al 1983, Patlak and Blasberg 1985).
Placement of a circular region of interest (mean area 1.5 cm2) within the 
boundaries of the aorta allowed the time to aortic peak enhancement to be 
identified. A contrast medium bolus tracking scan (CARE bolus, Siemens Medical 
Solution, Forchheim, Germany), located at the level of the aortic arch, was 
commenced at the same time as contrast agent administration. The dynamic
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study was manually triggered when peak aortic enhancement was identified on 
the bolus tracking enhancement graphs visualised on the console screen, and 
enhancement seen to fall; this was typically started within 3 to 5 seconds of the 
peak. This study, encompassing the entire tumour, consisted of a total of 8  
breath-hold helical acquisitions in expiration using the following parameters: 
80kV, 120mAs, table feed 30mm, rotation time 0.5seconds, detector width
1.5mm, reconstruction width 2mm ,SFOV 500mm, matrix 512mm. 80kV was 
chosen in preference to the standard 120kV to minimise radiation dose, as 
available data from the cranial circulation shows that there is no significant 
change in image quality at 80kV, despite a lower dose (Wintermark et al 2000). A 
further advantage of using 80kV for perfusion assessment is the better X-ray 
absorption of iodine at a lower kV. In between each of these 8  acquisitions, the 
patient was asked to breathe in and out, and to hold their breath. Total dynamic 
acquisition time varied from patient to patient depending on the tumour coverage 
required. Typically, each breath-hold acquisition was in the order of 3  to 6  
seconds depending on tumour size, with a 7 second breathing interval between 
each acquisition, thus the entire dynamic acquisition was of the order of 90 
seconds for a large tumour.
2.2.2 Data post-processing and analysis
Data was transferred to a dedicated workstation (Leonardo; Siemens Medical 
Solutions, Forchheim, Germany). Each dynamic study consisted of nine helical 
scans (baseline scan and eight post contrast scans), that required post­
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processing prior to quantitative analysis. For each scan, the 2mm axial images 
were reformatted into 10mm axial slices, overlapping by 5mm, using 3D software 
(3D analysis; Siemens Medical Solutions, Forchheim, Germany), to permit slice- 
by-slice analysis of the whole tumour within a clinically acceptable time.
These reformatted scans were checked to ensure that the entire tumour had 
been included. The image corresponding to the same tumour level along the z- 
axis of the patient was selected from each of the nine scans (one unenhanced 
and eight post-contrast dynamic scans) so that quantification could be performed 
for each level along the z-axis until the entire tumour was evaluated. It was 
possible to select images at a similar position along the tumour z-axis on all nine 
scans as image reformatting was performed previously from the same position; 
this was achieved by comparing the tumour position to adjacent anatomical 
structures. Then, each reformatted 10mm axial image from the same position 
along the z-axis of the patient from each of the nine helical scans, was saved as 
a separate series on the workstation, for further analysis (Figure 2.2). Thus for 
every patient, depending on the tumour size, a number of series were obtained, 
encompassing the entire tumour; each series consisting of one baseline non­
contrast image and eight subsequent dynamic contrast enhanced axial images at 
the same tumour level.
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Figure 2.2 This series shows the reformatted pre-contrast and eight post­
contrast images from a single 10mm axial level; all images are 
at a similar position along the z-axis of the patient.
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Prototype software (Functional CT; Siemens Medical Solutions, Forchheim, 
Germany) based on the Patlak model was used for analysis of tumour vascularity. 
For each patient, the series of reformatted dynamic images, encompassing the 
whole tumour, were loaded into the software. The arterial input was determined 
from the bolus tracking scan images for each patient and an arterial time-shift of 
3 seconds was employed by the software. A circular region of interest (ROI) was 
placed within the aorta, using an electronic cursor and mouse. This enabled 
individualised arterial time enhancement changes to be inputted directly into the 
software analysis program, and this arterial input information was saved 
automatically by the software for subsequent quantification of vascular 
parameters.
A ROI was drawn freehand around the tumour by the observer using an 
electronic cursor and mouse, taking care to exclude surrounding air, or 
atelectatic lung tissue. Subsequent software processing was automated: the 
change in Hounsfield unit over time, following contrast administration, of each 
pixel within the selected ROI, was transformed to generate coloured functional 
parametric maps of tissue vascularity based on Patlak analysis for the tumour 
ROI (Figure 2.3). Each pixel location within the functional map corresponded to a 
single quantitative value resulting from the mathematical calculation of the data 
at that location, that is, analysis was on a pixel-by-pixel basis. This process was 
repeated for each contiguous axial level, until the entire tumour had been 
covered (Figure 2.4). Finally, a global value representing the vascular parameter
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for the entire tumour was calculated by taking the median value of all individual 
pixels involved.
High K
LowK
Figure 2.3 Image from a single 10mm axial level shows the region of 
interest drawn freehand around a lung tumour using a mouse 
and electronic cursor, together with the corresponding 
coloured parametric map. Each pixel within the tumour map 
represents a vascular parameter value, in this case, the 
transfer constant K; the colour scale indicates red pixels as 
high K values and purple pixels as low K values.
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Figure 2.4 Coloured parametric maps from multiple contiguous axial 
levels encompassing the whole lung tumour. Each pixel 
location within the tumour region of interest (ROI) 
corresponds to a single quantitative vascular parameter value, 
in this case, the transfer constant K. A global value 
representing the vascular parameter for the entire tumour can 
therefore be calculated by taking the median value of all pixels 
involved.
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2.2.3 Patlak Analysis
The software used here is based on a simplified Patlak analysis (Patlak et al 
1983, Patlak and Blasberg 1985). This model assumes a one-way transfer of 
contrast from the intravascular into the extravascular-extracellular space. At any 
time point, the contrast concentration in tissue is equivalent to the sum of the 
intravascular and extravascular concentration of contrast as denoted by the 
following equation: c(t) = BV*b(t) + K*f b(t).dt, where c(t) is the concentration of 
contrast within the tissue, BV is the relative blood volume occupied by the 
vascular space of the tissue, b(t) is the concentration of contrast in blood, and K 
is the rate constant of transfer of contrast from the intravascular into the 
extravascular space. Dividing the equation by b(t) produces the linear equation: 
c(t)/b(t) = BV + K*f b(t).dt / b(t). For systems with irreversible accumulation over 
the time course of the experiment, a plot of c(t)/b(t) against f b(t).dt / b(t) results 
in a linear increase after sufficient equilibration time. By modifying the time axis in 
this way, Patlak analysis effectively transforms c(t)/b(t) versus time data into that 
which would have been observed had the arterial input function been constant 
throughout the experiment, with the terminal slope of the line equal to K 
(ml/100ml/min) and y-intercept relating to BV (ml/100ml) (Figure 2.5). The multi- 
phasic bolus infusion was therefore chosen to maintain arterial contrast as 
constant as possible following bolus loading, thus minimising the transformation 
required in the Patlak analysis.
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Figure 2.5 Patlak plot is shown for a study patient. The transfer constant 
K is derived from the gradient of the line, and relative blood 
volume (BV) from the y-intercept.
2.3 Discussion
Clinical assessment of vascular targeting drugs used in the treatment of cancer 
has highlighted problems when using conventional response criteria to quantify 
therapeutic effect (World Health Organisation 1979, Therasse et al 2000, Kerbel 
et al 2002). Morphological measurements can be unreliable for a number of 
reasons, especially the time lag between functional and anatomical changes and
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difficulties in defining the margins of an infiltrative tumour. Furthermore, tumour 
shrinkage may not occur with these drugs and therapeutic effect may be 
underestimated. For example, patients with colorectal cancer treated with the 
anti-angiogenic agent bevacizumab achieved a five month improvement in 
overall survival, despite only demonstrating a 1 0 % increase in objective tumour 
response (Hurwitz et al 2004). Consequently, functional assessment has been 
advocated, as direct quantification of tumour vascular biology is possible.
CT measurements of tumour vascular parameters are inherently variable due to 
a combination of intrinsic and extrinsic factors, including cardiac output, 
technique variability, instrument variability, observer variability, and tumour 
heterogeneity. It may be possible to compensate for some extrinsic factors, for 
example, reducing observer variability by using the same observer, and using 
individualised arterial input function for each patient. However, it is more difficult 
to compensate for the intrinsic heterogeneity in tumour perfusion as the tumour 
microcirculation exhibits spatial heterogeneity (Chaplin et al 1995, Kimura et al 
1996). Hence, perfusion CT measurement results obtained from a single 2mm 
axial tumour slice will be different from measurements made on the neighbouring 
slice or one 10mm away. To compensate for the spatial variation in tumour 
perfusion, a solution is to increase the tumour volume assessed by perfusion CT.
The use of MDCT allows for improved spatial resolution, reduced scanning time, 
and the ability to scan a larger tissue volume. By acquiring multiple helical
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acquisitions dynamically, assessment of an entire tumour volume is possible, 
which may decrease measurement error, thus improving measurement 
reproducibility. This is particularly important when repeated measurements are 
made on the same patient, for example, when assessing therapeutic drug 
effects. Furthermore, single level measurements have been problematic for 
quantitative assessment of perfusion in lung lesions, not least because of image 
mis-registration from respiratory motion during scan acquisition. For example, 
Miles et al (2001) reported that six out of 16 CT perfusion studies could not be 
analysed because of this. Using the described whole tumour helical acquisition 
technique, it was possible to assess the entire tumour successfully in all studies 
performed.
Patlak analysis of perfusion CT data has been validated against animal studies 
(Pollard et al 2004), used to assess kidney function and lymphoma disease 
activity, and to monitor tumour vascular response to therapy (Dawson and Peters 
1993, Ford et al 1996, Dugdale et al 1999, Miles et al 1999, Harvey et al 1999). 
This simplified analysis assumes a one-way transfer of contrast from the 
intravascular into the exravascular-extracellular space. The CT iodinated contrast 
used in clinical practice is freely diffusible between the intravascular and 
extravascular-extracellullar space and does not have intracellular uptake. 
Previous investigators have not taken into account contrast back-flow (K2), or 
intracellular movement (K3 and K4), as no intracellular uptake occurs. The 
amount of back-diffusion depends on the concentration difference between the
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extravascular and intravascular compartment. By using a multi-phasic contrast 
infusion protocol, the intravascular concentration remained high, and back-flow 
from the extravascular compartment can therefore be minimised, making the 
above assumption valid. This is especially so during the short acquisition time of 
about 90 seconds used in this study.
The transfer constant, K, is defined by the equation K=E*F where E, the 
extraction fraction, is defined by E=1-e( PS/F), therefore K is a function of both flow 
(F) and the permeability surface area product (PS) (Renkin 1959, Crone 1963). 
From the literature in humans, values of F in extra-cranial tumours range from 30 
to 100ml/100ml/min in lung cancer, 91.1 ml/100ml/min in rectal cancer, and 
1 0 1 ,5ml/100ml/min in head and neck cancer, while PS values range from
14.1 ml/1 OOml/min in rectal cancer and 25.3ml/100ml/min in head and neck 
cancer (Kiessling et al 2004, Gandhi et al 2006, Goh et al 2006). From the data 
in Chapter 3, the mean K value in untreated lung tumours from 18 patients is
11.1 ml/100ml/min. Using the Renkin and Crone equation above, PS = -F*LN(1- 
K/F). By inputting F values of between 30 and 100ml/1 OOml/min, PS values will 
range from 11.8 to 13.9ml/100/min. Thus the K values measured here for 
untreated tumours appear to approximate PS and not F. This approximation will 
hold true as long as tumour blood flow is much higher than PS. However, it is 
noted that experimental conditions will change following therapy, for example, 
after radiation treatment, F might increase significantly and K will approximate to 
PS, or after treatment with a vascular targeting drug, F decreases and K might
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then approximate to F. Interpretation of K is therefore dependent on knowledge 
of drug mechanism of action, which in novel agents, might be limited.
Volumetric perfusion CT is technically feasible and allows the measurement of 
vascular parameters in entire tumour volumes. However, there are several 
factors limiting the use of perfusion CT to perform whole tumour vascular 
measurements in everyday clinical setting. First, currently available CT 
technology does not allow whole tumour measurements of blood flow, as a much 
faster scanning speed of up to one scan per second is required. Although this 
might change with technological advances, the radiation dose implications of 
volumetric scanning at higher temporal resolution will have to be taken into 
account in human studies. However, BV is a relatively insensitive vascular 
parameter, since flow changes with very small changes in vessel calibre, and 
therefore any BV changes observed, may reflect greater reductions in blood flow. 
Second, data analysis was performed using prototype software which is not 
generally available; again, that might change in the near future. The software is 
also not fully automated. In order to evaluate the entire tumour, regions of 
interest were drawn manually around the tumour on individual 1 0 mm axial slices 
overlapping by 5mm, which depending on the size of the tumour can be both 
time and labour intensive. For example, the average lung tumour diameter in the 
repeatability study (Chapter 3) is about 8 cm, which is divided into 16 contiguous 
slices; each slice was analysed individually. Also, the variation amongst different 
observers in defining lung tumour volumes even when following a defined
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protocol is well recognised (Senan et al 1999). Finally, the tumour 
microcirculation is in a continuous state of flux, and perfusion CT vascular 
measurements merely provide a “snap-shot” of the microvascular function at the 
point when the scans were acquired. For example, an increase in blood volume 
in one tumour microregion combined with a similar degree of decrease in another 
would, using this method, imply no change in blood volume. However, 
measurements of a global change in tumour vascularity remain valid as response 
to treatment is based on the whole tumour.
In summary, volumetric perfusion CT permits quantitative whole tumour 
measurements of vascularity. Whole tumour assessment is a step in the 
direction for improving the reliability of tumour vascular measurements.
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CHAPTER 3 
MEASUREMENT REPEATABILITY OF VOLUMETRIC PERFUSION 
COMPUTED TOMOGRAPHY
3.1 Introduction
For any clinical measurement method to have practical utility it should be 
reproducible. Ideally, measurements made by the same method, on the same 
subjects, but using a different instrument, by different operators, and in different 
settings should produce identical results (British Standards Institution). However, 
this is not realistic in routine clinical practice because the measurement result 
obtained, especially in biological measurements, is often subject to intrinsic and 
extrinsic sources of variability. Therefore, measurements are considered to be 
repeatable if the same results are obtained by the same method, on the same 
subjects, using the same instrument, in the same setting, and within a short 
interval of time (British Standards Institution). In everyday clinical practice, a 
measurement method would be considered to be repeatable if the variation 
observed after repeated measurements on the same patients, and without 
intervening therapy, is small enough relative to the magnitude of actual biological 
changes observed following therapy. Extrinsic causes of variation can be due to 
the measurement instrument itself, the acquisition technique, patient compliance, 
and the skill and experience of the operator. Inter and intra-observer variation is 
an important source of measurement variability. It is also recognised that the
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tumour blood supply is intrinsically variable, and the tumour microcirculation 
exhibits spatial and temporal heterogeneity (Kimura et al 1996, Chaplin et al 
1995), which contributes to the biological variation affecting measurement results. 
While the day-to-day variation in functional vascular measurements might be 
unavoidable, assessment of whole tumour volumes may compensate for spatial 
heterogeneity. Volumetric perfusion CT allows the measurement of tumour 
vascular parameters throughout the entire tumour volume, and may potentially 
improve measurement repeatability as compared to conventional single level 
imaging techniques. To date, there is little reported data on tumour vascular 
measurement repeatability using CT, which is clearly relevant to therapeutic 
assessment where a magnitude of change is measured to assess effect.
3.2 Aim
The aim of this chapter is firstly, to evaluate the repeatability of whole tumour 
vascular measurements in patients with non-small cell lung cancer using 
volumetric perfusion CT. Secondly, in order to test the hypothesis that 
measurement repeatability of perfusion CT improves with greater tumour volume 
coverage, the vascular measurements derived from a whole tumour volume are 
compared to measurements from a 40mm z-axis coverage (four contiguous 
tumour levels), and a 10mm z-axis coverage (single tumour level). Thirdly, to 
evaluate inter and intra-observer variability of volumetric perfusion CT.
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3.3 Patients and Method
3.3.1 Study Design
Local research ethics committee approval was obtained, with explicit approval for 
radiation exposure of patients for research purposes as required under the 
Ionising Radiation (Medical Exposure) Regulations (IR(ME)R). Each patient gave 
written informed consent, which included information on the radiation exposure 
from the CT examinations (7.5mSv per examination). Eighteen patients (11 
males, 7 females, mean age 6 8  years) with histologically proven, inoperable non­
small cell lung cancer (mean tumour size 8.0cm, range 4.9 to 11.8cm) were 
enrolled into the study. Paired perfusion CT examinations were performed on 
each of the 18 patients; the second CT study was performed within 24 hours of 
the first study, without therapeutic intervention, using identical technical 
parameters.
3.3.2 Volumetric perfusion CT
The CT methodology, image post-processing and data analysis have been 
described in Chapter 2. Each of the 18 patients had two perfusion CT studies, 
and as much as possible, images from each tumour slice from both studies were 
co-registered by comparing the tumour position to adjacent anatomical 
structures. As before, Patlak analysis (1983 and 1985) was used to quantify (i)
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transfer constant (K; ml/1 OOml/min) which provides information on permeability 
surface area product and blood flow, and (ii) relative blood volume (BV; 
ml/100ml) on a pixel-by-pixel basis. Thus quantification of vascular parameters 
for the whole tumour was carried out on all 36 studies to allow assessment of 
repeatability
In order to determine if CT vascular measurement repeatability improves with 
increasing z-axis tumour coverage, additional analysis was carried out on the 18 
patients by comparing vascular measurements derived from the whole tumour, to 
measurements obtained from 40mm z-axis tumour coverage (four contiguous 
tumour levels), and from 10mm coverage (single tumour level). Following image 
post-processing, a single central 1 0 mm tumour level was chosen, and using the 
perfusion software, a region of interest (ROI) was drawn freehand around the 
tumour. As before, each pixel location within the functional map generated for the 
ROI corresponded to a single quantitative vascular value resulting from the 
Patlak calculation of the data at that location. Data was analysed on a pixel-by- 
pixel basis, and median values of tumour K and BV were derived for this single 
10mm tumour level. These values were recorded for each patient. This process 
was repeated for another three adjacent tumour levels. By amalgamating data 
from all individual pixels from these three levels and the initial tumour level, a 
median value for K and BV was calculated, producing values for a z-axis 
coverage of 40mm (Figure 3.1).
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(a)
High K
Low K
(b)
Figure 3.1 A region of interest (ROI) was drawn freehand around the lung 
tumour in a study patient and coloured parametric maps of the 
vascular parameter, in this case, the transfer constant (K) are 
automatically generated by the perfusion software for this 
10mm tumour coverage (a). By repeating the process for 
another three adjacent tumour levels in the same patient, and 
amalgamating data from all individual pixels from the four 
levels, tumour K values can be derived from a 40mm z-axis 
coverage (b). The colour scale indicates red pixels as high K 
values and purple pixels as low K values.
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Again, these values were recorded for each patient. The same process was 
repeated for the second perfusion CT study from each of the 18 patients, 
ensuring similar tumour levels as the first study were analysed, to allow for 
assessment of measurement repeatability.
In order to determine inter-observer variability, the scan images from the first 10 
of the 18 patients were analysed using the same method as described in Chapter 
2, by a second independent observer (Dr Vicky Goh, Consultant Radiologist) who 
has six years experience of perfusion CT and nine years experience of chest CT. 
The 20 scans performed on the 10 patients were analysed by both observers, 
and values for K and BV were recorded for each study. To determine intra­
observer variability, the images from the 2 0  studies were re-analysed by both 
observers after an interval of four weeks to reduce recall bias.
3.3.3 Statistical analysis
Statistical analysis was performed using StatsDirect statistical software version 
2.3.8 (StatsDirect Ltd, Sale, Cheshire, United Kingdom). Bland and Altman 
(1986) repeatability statistics were applied as a means of quantifying 
measurement error of the volumetric perfusion CT technique. The same statistics 
were applied to assess the inter and intra-observer variability, and used to 
compare the repeatability of whole tumour volumetric measurements with 
conventional four and single level measurements
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Initial analysis was performed to confirm that the statistical assumptions required 
for repeatability analysis were upheld. Kendalls t was used to establish any 
correlation between the absolute difference and the mean; if the difference 
appeared to increase when the mean parameter value increased, the data was 
transformed by natural logarithm. Using Bland and Altman statistics, the mean, 
standard deviation, mean difference, and 95% limits of agreement for each 
vascular parameter were established. The following statistical measurements of 
repeatability were derived:
1. The square root of the mean squared difference (dSD) was
calculated, where d is the difference between repeated 
measurements, and n is the number of patients.
dSD = \ '( I d 2/n)
2. The within patient standard deviation (WSD) was calculated from:
WSD = dSD/V2
3. The within patient coefficient of variation (WCV) was calculated by
dividing the WSD by the overall mean of each parameter. For 
logarithmic transformed data, the WCV was calculated from:
WCV = exp(WSD)-1
4. The repeatability coefficient (r) was calculated from:
r = 2.77 x WSD (=1.96 xdSD)
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For logarithmic transformed data, this can be expressed as a 
percentage of the mean:
%r = 100 x exp(LNmean ± r) / mean
5. To calculate the 95% confidence interval (Cl) for change which 
might occur in ‘n’ patients
Cl = ± (1.96 x dSD) / \'n
For logarithmic transformed data, this can be expressed as a 
percentage of the mean:
%CI = 100 x exp(LNmean ± Cl) / mean
6. The ratio of the between patient variance and within patient 
variance was assessed using one-way analysis of variance, and 
tested for significance.
7. The intra-class correlation coefficient was derived.
3.4 Results
3.4.1 Within subject measurement repeatability
All 18 patients completed their scans; all 36 studies were technically adequate, 
included the entire tumour and were analysed successfully. K values were 
transformed by natural logarithm because the difference in mean values 
increased when the mean parameter value increased (Kendalls tau, p<0.05).
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The mean, mean difference, 95% limits of agreement and repeatability statistics 
are presented in Table 3.1. The Bland and Altman agreement plot showing the 
95% limits of agreement for K, and the corresponding scatter plot of K values 
from both scans against the line of perfect agreement are shown in Figure 3.2. 
The Bland and Altman agreement plot and the corresponding scatter plot of BV 
are shown in Figure 3.3. Both tumour K and BV showed acceptable agreement 
between studies as demonstrated by WCV of 10.4% and 23.6% respectively. 
Intraclass correlation coefficient for K and BV were 0.90 and 0.70 respectively.
Table 3.1 Repeatability statistics from paired studies performed on 18 
patients measuring whole tumour blood volume (BV) and 
transfer constant (K)
(a) K (ml/100ml/min) (b) BV (ml/100ml)
Mean (SD) 11.1 (4.1) 5.6 (2.3)
Mean difference -0.09 1.0
95% limits o f agreement -4.0 to 3.4 -2.2 to 4.2
WSD 0.10a 1.3
WCV 10.4%a 23.6%
Repeatability 0.27a 3.6
ICC 0.90 0.70
Variance ratio 19.5 (p<0.001) 6.0 (p<0.001)
SD -  standard deviation; WCV -  within subject coefficient of variation; ICC -  
intraclass correlation coefficient; WSD -  within subject standard deviation 
aLn transformed data
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Figure 3.2 Bland-Altman agreement plot (a) of the difference between the 
two scans against the mean of the transfer constant (K) values 
from the two scans. The mean difference is indicated by the 
solid line. The two outer dotted lines represent the 95% limits 
of agreement, which define the range within which most 
differences between repeated K measurements made on the 
same subject will lie. Scatter plot (b) of K measurements from  
the two scans, with a line of perfect agreement, which 
represents the line all points would lie on if both 
measurements gave the same reading. This plot provides a 
visual demonstration of how precise the two sets of 
measurements are. The closer the measurements lie to this 
line of equality, the better the agreement.
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Figure 3.3 Bland-Altman agreement plot (a) of the difference between the 
two scans against the mean of the blood volume (BV) values 
from the two scans. The mean difference is indicated by the 
solid line. The two outer dotted lines represent the 95% limits 
of agreement, which define the range within which most 
differences between repeated BV measurements made on the 
same subject will lie. Scatter plot (b) of BV measurements from 
the two scans, with a line of perfect agreement, which 
represents the line all points would lie on if both 
measurements gave the same reading. This plot provides a 
visual demonstration of how precise the two sets of 
measurements are. The closer the measurements lie to this 
line of equality, the better the agreement.
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Apart from demonstrating measurement agreement, the statistics can potentially 
be used to assess if a change in measurement value following therapy is 
significant. From the BV repeatability dataset above, a clear outlier was identified 
which cannot be explained by any technical factors. For this patient, the 
difference in BV from the two scans was greater than four times the standard 
deviation of the differences from all patients and was excluded (Figure 3.4). 
Outliers were also identified from the K repeatability dataset. However, as more 
than one outlier was present, these data were included. Analysis was therefore 
carried out on the remaining 17 patients. The 95% limits of change for a group of 
n patients can be estimated from the value of dSD using the following formula: 
(1.96*dSD)/Vn. The dSD values for BV and logarithmically transformed K are 
1.05ml/100ml and 0.13ml/1 OOml/min respectively. Hence, for a group of 17 
patients, any change in tumour BV of more than ±9.2% as a consequence of 
treatment would be over and above measurement variability, i.e. the probability 
of this change being random is less than 5%. Similarly, an increase in tumour K 
of more than 6.5%, or reduction more than 6.1% for a group of 17 patients would 
be statistically significant at the 5% level; this was asymmetric about the mean as 
K was logarithmically transformed.
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Figure 3.4 Scatter plots of consecutive patients showing the absolute 
difference from repeated scans for blood volume (BV) (a) and 
transfer constant (K) (b). Outliers were identified as having 
differences greater than twice the standard deviation of the 
differences from all 18 patients.
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3.4.2 Whole tumour versus four levels versus single level perfusion CT 
measurements
Additional analysis was performed on the 18 patients to compare the 
repeatability of perfusion CT vascular measurements derived from a whole 
tumour volume and compared to measurements from a 40mm z-axis coverage 
(four contiguous tumour levels) and a 10mm z-axis coverage (single tumour 
level). The mean, mean difference, 95% limits of agreement and repeatability 
statistics for K and BV measurements from 10mm z-axis coverage, 40mm z-axis 
coverage and the whole tumour for the 10 patients are summarised in Table 3.2. 
Bland-Altman agreement plots and scatter plots for K and BV are shown in 
Figure 3.5 and Figure 3.6.
WCV for K measurements was 21.7% from a 10mm coverage, improving to 
12.6% for 40mm coverage, and 10.4% for the whole tumour volume. Similarly, 
the WCV for BV measurements was 38.7% from a 10mm coverage, improving to 
29.3% for 40mm coverage, and 23.6% for the whole tumour volume. These 
results demonstrate that by increasing z-axis coverage from 10mm to 40mm, and 
ultimately by analysing the whole tumour volume, improvement in repeatability 
for tumour vascular measurements can be achieved.
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Table 3.2 Repeatability statistics from 10mm, 40mm and whole 
tumour measurements
10mm 40mm Whole tumour
(a) K (ml/100ml/min)
Mean (SD) 11.2 (5.1) 10.9 (4.4) 11.1 (4.1)
Mean difference -0.08 0.04 -0.09
95% limits of agreement -6.3 to +6.1 -4.5 to +4.6 -4.0 to +3.4
WSDa 0.20 0.12 0.10
WCV0 21.7% 12.6% 10.4%
Repeatability3 0.54 0.33 0.27
ICC 0.83 0.87 0.90
Variance ratio 11.0 (p<0.001) 15.1 (p<0.001) 19.5 (p<0.001
(b) BV (ml/100ml)
Mean (SD) 5.8 (2.6) 5.5 (2.4) 5.6 (2.3)
Mean difference 1.1 1.1 1.0
95% limits of agreement -4.8 to +7.0 -3.0 to +5.1 -2.2 to +4.2
WSD 2.2 1.6 1.3
WCV 38.7% 29.3% 23.6%
Repeatability 6.2 4.4 3.6
ICC 0.45 0.62 0.70
Variance ratio 2.8 (p=0.018) 4.5 (p=0.0013) 6.0 (p<0.001)
SD -  standard deviation; WCV -  within subject coefficient of variation; ICC -  intraclass 
correlation coefficient; WSD -  within subject standard deviation 
aLN transformed data
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Figure 3.5 Bland-Altman agreement plots (a) of the difference in transfer 
constant (K) between the two scans against the mean of the K 
values for a 10mm, 40mm and whole tumour coverage. The 
narrowing of the 95% limits of agreement with whole tumour 
coverage compared to 10mm and 40mm coverage indicates an 
improvement in measurement repeatability. Scatter plots (b) of 
K measurements from the two scans with a line of perfect 
agreement, for a 10mm, 40mm and whole tumour coverage. 
As tumour coverage increases from 10mm to 40mm to whole 
tumour, the measurements become closer to the line of 
equality, indicating an improvement in agreement, and hence 
the precision of the measurements.
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Figure 3.6 Bland-Altman agreement plots (a) of the difference in blood 
volume (BV) between the two scans against the mean of the 
BV values for a 10mm, 40mm and whole tumour coverage. The 
narrowing of the 95% limits of agreement with whole tumour 
coverage compared to 10mm and 40mm coverage indicates an 
improvement in measurement repeatability. Scatter plots (b) of 
BV measurements from the two scans with a line of perfect 
agreement, for a 10mm, 40mm and whole tumour coverage. 
As tumour coverage increases from 10mm to 40mm to whole 
tumour, the measurements become closer to the line of 
equality, indicating an improvement in agreement, and hence 
the precision of the measurements.
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3.4.3 Observer Variability
Inter and intra-observer variability was evaluated in the first 10 patients recruited 
onto the study. There was good agreement between and within observers for 
both vascular parameters (Table 3.3), as indicated by a coefficient of variation 
between 3.5%  and 3.6%  for inter-observer variation and 3.3 % and 6.3%  for 
intra-observer variation. Intraclass correlation coefficient for inter and intra­
observer variability for both vascular parameters ranged from 0.97 to 0.99.
Table 3.3 Inter- and Intra-observer agreement from ten patients for 
whole tumour transfer constant (K) and blood volume (BV) measurements
Vascular
measurement
Agreement Mean difference
(95% limits of 
agreement)
WCV ICC
K (ml/100ml/min) Inter-observer 0.07 (-1.01 to +1.08) 3.47% 0.99
Intra-observer 1 0.49 (-2.08 to +1.11) 6.34% 0.97
Intra-observer 2 0.15 (-0.87 to +1.17) 3.50% 0.99
BV (ml/100ml) Inter-observer 0.44 (-0.59 to +0.68) 3.64% 0.99
Intra-observer 1 0.09 (-0.64 to +0.45) 3.30% 0.99
Intra-observer 2 0.01 (-0.68 to +0.70) 3.95% 0.99
WCV -  within subject coefficient of variation; ICC -  intraclass correlation coefficient
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3.5 Discussion
Volumetric perfusion CT allows the measurement of tumour vascular parameters 
throughout an entire tumour volume, thus providing a more accurate 
representation of the spatial heterogeneity of the tumour microcirculation. Bland 
and Altman statistics were applied as a means of quantifying measurement 
variability, and hence the repeatability of the perfusion CT technique. This study 
has shown that vascular measurements derived from the whole tumour volume 
are repeatable, and indeed, improves on measurement repeatability when 
compared to conventional single level analysis. This is particularly salient when 
serial measurements are made on the same patient, for example when 
assessing response after therapy.
Measurement repeatability can be evaluated using several indices. The 95% 
limits of agreement represents the boundaries within which the true 
measurement is expected to lie 95 percent of the time; the narrower the limits, 
the more precise the measurement being made. The repeatability coefficient 
indicates the 95% confidence limits that might occur spontaneously in an 
individual. The WCV quantifies the measurement error with respect to the mean, 
and provides an estimation of precision. The variance ratio compares the 
between patient variance and within patient variance, and a parameter with a 
larger variance in the patient population and a smaller variance within individual 
patients (and thus a higher ratio) is ideal for therapeutic monitoring. Finally, the
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intra-class correlation coefficient provides a measure of the reliability of the 
measurement method.
We found that both K and BV measurements were repeatable, although K 
measurements were less variable than those for BV. This may be related to the 
mathematical basis of Patlak analysis where smaller changes in the gradient of 
the Patlak plot will produce greater changes in the y-intercept and BV 
measurements will show greater variability compared with K.
The repeatability results derived from whole tumour volume measurements are 
comparable with published CT data of repeatability for both animal and human 
subjects. Our WCV of 10.4% and 23.6% for K and BV respectively is similar to 
variability in cranial perfusion of 12 to 35% in dogs (Nabavi et al 1999), and 13 to 
33% in rabbits (Purdie et al 2001), and cerebral tumour perfusion of 14 to 24% in 
rabbits (Cenic et al 2000). Indeed, our results compare favourably to single level 
DCE-MRI repeatability in a variety of human tumours (Galbraith et al 2002) 
where the WCV in logioKtrans, a measurement akin to K, was 24%. Furthermore, 
there was good agreement between and within observers, and the intraclass 
correlation coefficient of between 0.97 and 0.99 compare favourably to previous 
studies of observer variability where intraclass correlations of about 0.75 were 
achieved (Fiorella et al 2004, Goh et al 2005); this bodes well for clinical utility of 
this technique.
The results also demonstrate that the variability is within the accepted limits for 
therapeutic agents currently being assessed in clinical trials. In a phase 1 study 
of the anti-angiogenic agent bevacizumab in rectal cancers, mean reduction in 
blood volume of 26% in four patients was demonstrated using single level 
perfusion CT (Willett at al 2004). In a phase 1 study of CA4P assessed using 
single level DCE-MRI, mean logioKtrans value, was reduced by 37% for nine 
patients after drug administration (Galbraith et al 2003). Using the repeatability 
statistics for the same number of patients, volumetric perfusion CT would be 
sensitive to reductions in BV of greater than 18.9%, and would be able to detect 
significant reductions in K greater than 8.3%. Therefore, the level of therapeutic 
change seen in these two studies is greater than the measurement variability of 
whole tumour perfusion CT.
This study has demonstrated that measurement repeatability can be improved by 
increasing tumour volume coverage. For example, an improvement in the 
repeatability coefficient from 0.54 to 0.33 to 0.27 was demonstrated for tumour K 
when tumour coverage increased from 10mm to 40mm to the whole tumour 
volume, indicating a decrease in measurement variability. This was also 
supported by the ratio of between-patient variance to within-patient variance, 
which increased from 11.0 to 15.1 to 19.5, indicating that vascular measurements 
derived from a greater tumour volume may be more sensitive to population 
variations in the parameter studied, and less variable when repeated studies are 
performed on the same individual.
The sample size for this repeatability study is small. However, a recent study 
looking at the effects of increasing number of patients on measurement 
repeatability of DCE-MRI vascular parameters concluded that there was little 
improvement in repeatability once 20 patients were recruited (Taylor et al 2006). 
Furthermore, the number of patients in this study is consistent with repeatability 
studies on functional imaging of vascular physiology reported in the literature, 
where the majority of studies recruited between 10 and 20 patients (Laking et al 
2006). Nevertheless, it is clearly important to incorporate repeatability analysis 
into future studies of functional imaging in order to be confident that the 
measurements obtained are reliable.
While we have established that repeatability of perfusion CT measurements can 
be improved with increasing tumour coverage, one limitation of this analysis is 
that it merely provides an overall measure of measurement variability. It does not 
distinguish between the extrinsic factors that contribute to this variability, 
including acquisition technique, patient compliance with breath-holding and 
observer variability, and the intrinsic factors such as tumour heterogeneity. 
However, on a practical level, identical scan acquisition parameters and 
technique were employed in each of the paired studies, and analysis was 
performed by a single observer using the same software package, minimising 
variability from these factors. It is therefore a reasonable assumption that
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compensation for intrinsic spatial heterogeneity is a major factor contributing to 
this improvement.
In summary, we have shown that perfusion CT measurements derived from 
whole tumour volume evaluation are repeatable and that measurement 
repeatability improves with increasing tumour coverage. Assessing tumour 
vasculature over a greater tumour volume may provide more reliable assessment, 
and should be considered in clinical practice.
CHAPTER 4
TUMOUR VASCULAR EFFECTS OF FRACTIONATED RADIOTHERAPY IN 
HUMAN NON-SMALL CELL LUNG CANCER
4.1 Introduction
Nearly 50% of patients with cancer will undergo radiotherapy as part of their 
treatment (Jemal et al 2005). Radiotherapy is an important component of the 
radical treatment of many localised cancers. For lung cancer, radiotherapy is a 
major treatment modality; radical radiotherapy is offered for potentially curable 
tumours, and palliative radiotherapy for symptomatic relief of advanced disease. 
In the palliative setting, lower doses may be employed to achieve tumour 
regression and growth delay rather than hope to completely eradicate all tumour 
cells; this is achieved using fewer larger fractions over a shorter overall time, for 
example, two to three weeks, compared to four to six weeks for radical treatment. 
However, even for radical regimens, treatment failure will occur in a significant 
number of patients, and manipulation of the tumour vasculature has emerged as 
a promising therapeutic strategy over the past few years (Herbst et al 2005). 
Anti-angiogenic agents that impede tumour neo-vascularisation and vascular 
disrupting agents that target established tumour blood vessels are currently in 
clinical trials, and are being integrated with fractionated radiotherapy regimens, 
with the aim of improving treatment effectiveness.
114
There has been little human data on the effects of radiation on tumour 
vasculature. Recent pre-clinical data has indicated that the tumour response to 
radiation may be regulated by the degree of apoptosis in tumour endothelial cells, 
suggesting that the tumour vasculature may be an important therapeutic target 
for radiation (Garcia-Barros et al 2003). There is also evidence that radiation 
induced tumour regression may involve destruction of tumour vessels. It is also 
well recognised that tumour perfusion, through its effects on oxygenation, plays 
an important role in modulating responses to radiotherapy (Thomlinson and Gray 
1955).
To date, the acute in vivo effects of fractionated radiotherapy on tumour vessels 
have not been evaluated for human lung cancer. Assessment of the acute 
tumour vascular effects of ionising radiation in human tumours is needed to 
corroborate data suggesting that the tumour vasculature may be an important 
therapeutic target for radiation. It is also important to establish a baseline for 
future evaluation of combined therapy with vascular targeting drugs in human 
lung cancer.
4.2 Aim
The aims of this study was firstly, to measure in vivo the acute vascular effects of 
fractionated radiotherapy on an entire human lung cancer using volumetric
perfusion CT. Secondly, to describe the spatial distribution of these vascular 
effects by measuring the vascular changes at the rim and the centre of the 
tumour.
4.3 Patients and methods
4.3.1 Study design
Local research ethics committee approval was obtained, with explicit approval for 
radiation exposure of patients for research purposes as required under the 
Ionising Radiation (Medical Exposure) Regulations (IR(ME)R). Each patient gave 
written informed consent; this included information on the radiation exposure 
from both the CT examinations (7.5mSv per examination), and subsequent 
radiotherapy (27Gy total dose). Sixteen patients (nine males, seven females, 
mean age 71 years) with histologically proven, inoperable non-small cell lung 
cancer were enrolled prospectively into the study. All patients were treated with a 
course of hypo-fractionated palliative radiotherapy delivering 27Gy in six fractions 
of radiotherapy over three weeks (4.5Gy per fraction, two fractions per week). 
Using volumetric perfusion CT, all sixteen patients were scanned after the 
second fraction (9Gy total dose) of radiotherapy. Eight patients had additional 
scans after the fourth (18Gy total dose) and sixth (27Gy total dose) fractions of 
radiotherapy. All scans were performed within two hours of patients receiving 
radiotherapy.
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4.3.2 Volumetric perfusion CT
The CT methodology, image post-processing and data analysis have been 
described in Chapter 2. Apart from whole tumour measurements, additional 
image analysis was carried out on both the tumour rim and the tumour centre. 
The tumour rim was defined as the area less than 20% of the diameter from the 
tumour edge, and the tumour centre was defined as the area more than 30% of 
the diameter from the tumour edge. Because of difficulty in defining the tumour 
rim and the centre at the ends of the tumour volume, analysis was only carried 
out on a single central representative 10mm tumour axial level. As before, Patlak 
analysis (1983 and 1985) was used to quantify (i) transfer constant (K; 
ml/100ml/min) which provides information on permeability surface area product 
and blood flow, and (ii) relative vascular blood volume (BV; ml/100ml) on a pixel- 
by-pixel basis.
4.3.3 Statistical analysis
Paired t test was performed to compare mean changes in BV and K. In addition, 
Bland and Altman repeatability statistics (1986), as described in Chapter 3, were 
used to assess if an observed response following therapy is meaningful. The 
95% limits of change for a group of ‘n’ patients can be estimated from the value 
of the mean squared differences (dSD) derived from the repeatability data set 
using the following formula: (1,96*dSD)/\'n. From the repeatability data derived 
previously from 17 patients, the dSD values for BV and logarithmically
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transformed K were 1.05ml/100ml and 0.13ml/100ml/min respectively. Hence, for 
a group of sixteen patients, any change in tumour vascular BV of more than 
t 9.4%  as a consequence of treatment would be over and above intrinsic 
measurement variability, that is, the probability of this change being random is 
less than 5%. Similarly, an increase in tumour vessel K of more than 6.7%, or 
reduction more than 6.3% for a group of sixteen patients would be statistically 
significant at the 5% level. Likewise, for a group of eight patients, any change in 
BV of more than ±13.4%, or an increase in K of more than 9.6%, or reduction of 
more than 8.8% would be statistically significant at the 5% level.
4.4 Results
4.4.1 Whole tumour vascular changes
All 16 patients completed their radiation treatment and were scanned 
successfully. Mean tumour vascular BV and K measurements are summarised in 
Table 4.1.
Table 4.1 Mean (tstandard deviation) values for tumour transfer 
constant (K) and blood volume (BV) at baseline and after 
fractionated radiotherapy
Baseline 9Gy 18Gy 27Gy
K (ml/100ml/min)
W hole tum our 11.8 ± 3 . 3 13.0 ± 2 . 0 13.5 ± 3 . 0 13.7 ± 5 . 3
Tum our rim 14.3 ± 4 . 2 16.9 ± 5.6 20.7 ± 3.4 17.2 ± 6 . 4
Tum our centre 8.6 ± 3 . 8 8.9 ± 3.0 9.0 ± 2 . 6 8.3 ±5 . 1
BV (ml/100ml)
W hole tum our 5.8 ± 1.9 7.1 ± 3 . 0 7.4 ± 2 . 5 6.5 ± 2 . 0
Tum our rim 7.0 ± 2 . 6 9.3 ± 4 . 9 10.5 ± 5 . 8 10.2 ± 3 . 8
Tum our centre 3.4 ± 2.0 3.9 ± 2 . 0 4.1 ±2 . 1 3.5 ± 1.1
At baseline, whole tumour BV and K were 5.8ml/100ml and 11.8ml/100ml/min 
respectively. Both mean BV and K increased following radiotherapy (Figure 4.1). 
BV increased significantly from baseline by 21.5% (paired t-test, p=0.025), 27.1% 
(p=0.018) and 11.2% (p=0.0020) after the second (9Gy total dose), fourth (18Gy 
total dose), and sixth (27Gy total dose) fractions of radiotherapy respectively. 
These BV changes were greater than the 95% limits of change. K increased from 
baseline by 10.2% (p=0.065), 14.5% (p=0.37) and 16.2% (p=0.31) after the 
second, fourth and sixth fractions of radiotherapy. These changes in K were 
greater than the 95% limits of change derived from our repeatability data, but 
were not significant on paired t-testing.
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(a) (b)
Figure 4.1 Line graphs showing mean changes (±1 standard error) in 
whole tumour vascular blood volume (BV) (a) and transfer 
constant (K) (b) after fractionated radiotherapy. Measurements 
are derived from pixel-by-pixel analysis of whole lung tumour 
volumes and included pixels from both the more vascularised 
tumour rim as well as the relatively poorly perfused tumour 
centre.
1 2 1
4.4.2 Vascular changes in the tumour rim compared to the centre
The tumour vasculature was noted to be spatially heterogeneous with the tumour 
rim showing a higher BV and K than the centre. At baseline, the ratio of BV at the 
tumour rim to BV at the tumour centre was 2.1:1. For K, this was 1.7:1. Following 
radiotherapy, changes in vascular BV were greater at the tumour rim compared 
to the centre (Figure 4.2 and Figure 4.3). After the second fraction of 
radiotherapy, vascular BV increased by 31.6% (p=0.10) and 16.4% (p=0.29) at 
the rim and centre of the tumour respectively. These changes were greater than 
the 95% limits of change but were not significant on paired t-testing. After the 
fourth and sixth fractions of radiotherapy, vascular BV at the tumour rim 
increased significantly by 49.3% (p=0.034) and 44.6% (p=0.0012) respectively. 
Increase in vascular BV at the tumour centre was 19.9% (p=0.029) and 4.0% 
(p=0.0050) respectively. Again these changes were greater than the 95% limits 
of change.
High BV
Low BV
Figure 4.2 Coloured parametric maps depicting vascular blood volume 
(BV) at three contiguous axial levels from a lung tumour, at 
baseline (a) and after four fractions (18Gy total dose) of 
radiation therapy (b). Baseline tumour vascularity was 
spatially heterogeneous with the tumour rim being more 
vascular than the centre. A greater increase in BV after 
radiotherapy is observed at the tumour rim compared to the 
centre.
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Figure 4.3 Line graphs showing mean changes (±1 standard error) in 
tumour blood volume (BV) (a) and transfer constant (K) (b) at 
the tumour rim and the tumour centre following fractionated 
radiation therapy. Increases in both vascular parameters were 
greater at the tumour rim compared to the tumour centre.
• Tumour rim 
Tumour centre
0
Baseline 9Gy 18Gy 27Gy
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Changes in K after radiotherapy were greater at the tumour rim than the centre 
(Figure 4.3). At the tumour rim, K increased significantly by 18.4% (p=0.022) and 
44.8 % (p=0.0048) after the second and fourth fraction of radiotherapy 
respectively. These changes in K were also greater than the 95% limits of 
change. After the sixth fraction of radiotherapy, K at the tumour rim increased by 
20.5% (p=0.25) from baseline, which was greater than the 95% limits of change 
but was not significant on paired t-testing. At the tumour centre, K increased by 
3.5% (p=0.69) and 4.7% (p=0.27), and decreased by 2.9% (p=0.65) after the 
second, fourth and sixth fractions of radiotherapy respectively. These changes 
were not greater than the 95% limits of change and not statistically significant on 
t-testing.
4.5 Discussion
The spatial distribution of K and BV on the baseline coloured parametric maps of 
the lung tumours in this study demonstrate that the tumour periphery is more 
vascular relative to the centre. This is consistent with pre-clinical studies in rat 
sarcomas showing that macroscopically, the tumour vasculature, although 
chaotic, and lacking the branching pattern of normal vessels, is ordered in 
distinct spatial regions (Endrich et al 1979). The centre of the tumour is relatively 
avascular, and is surrounded by a semi-necrotic region; a relatively stable 
microcirculation is evident at the periphery of the tumour, with an advancing 
vascular front at the tumour rim.
Ionising radiation causes cell death through accumulated single and double 
strand DNA damage mediated by both a direct effect of the photon passage 
through a cell and an indirect effect due to the production of free radicals, in 
particular the hydroxyl free radical; this latter effect is considered the dominant 
mode of DNA damage after therapeutic radiation. The interaction between 
ionising radiation and tumour vasculature has been studied in the laboratory. 
Recent in vitro studies have shown that the tumour response to radiation may be 
regulated by tumour endothelial cell apoptosis, indicating that the tumour 
endothelium is an important therapeutic target for radiation (Garcia-Barros et al 
2003). Up-regulation of VEGF, either directly, or through activation of 
endothelium HIF-1, has also been reported in various cancer cell lines after 
ionising radiation, which may result in increased perfusion and neo-vessel 
formation (Moeller et al 2004, Lund et al 2004, Ando et al 1998). In mice, 
increase in tumour perfusion and subsequent increase in oxygenation were 
observed within four hours of fractionated radiation (Crokart et al 2005). This was 
thought to be due to an acute tumour inflammatory response. It has also been 
shown that tumour perfusion increases about 24 hours after radiation, which is 
mediated by endothelial nitric oxide (Sonveaux et al 2002). The mechanism of 
tumour re-oxygenation, which is essential to the enhancement of radio-sensitivity 
following irradiation, is therefore partly due to decrease in oxygen consumption 
and better diffusion secondary to tumour cell loss, as well as an increase in 
tumour perfusion.
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Our findings bear out these pre-clinical findings of increased perfusion following 
ionising radiation. Whole tumour BV increased in vivo following radiotherapy. BV 
changes were evident as early on as the first two fractions of radiotherapy, 
indicating that a dose of 9Gy was sufficient to cause measurable increases, and 
remained significantly raised compared to baseline following 18Gy and 27Gy of 
radiotherapy. There did not appear to be a radiation dose response in terms of 
vascular changes as BV increased after two fractions without further significant 
increase after the fourth and sixth fractions of radiotherapy. The vascular 
changes were spatially heterogeneous. Although significant increases were 
noted both for the tumour rim and centre, changes were greater at the tumour rim. 
This may in part reflect the distribution of the vascularisation, but may also reflect 
the mechanism of radiation effect: vasodilatation of perfused established vessels 
secondary to release of inflammatory cytokines, opening up previously non­
perfused vessels, and neovessel formation due to upregulation of VEGF, and 
expression of endothelial NOS.
Changes in K did not closely parallel changes in BV. Whole tumour K did not 
appear to increase significantly following radiotherapy. When changes at the 
tumour rim were compared with the centre, significant changes were found, 
suggesting that K change was more spatially dependent than BV change. 
Significant K change occurred at the tumour rim after the second and fourth 
fractions of radiotherapy, possibly reflecting increased vessel leakiness and
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endothelial cell damage. However no significant change in K was identified 
following the sixth fraction of radiotherapy, which may be due to establishment of 
equilibrium between vessel permeability and interstitial pressure.
While there have been no in vivo human studies monitoring the acute tumour 
vascular effects over an entire course of fractionated radiotherapy, our results 
are broadly in line with the few studies that have evaluated vascular changes in 
patients treated with radiotherapy or chemo-radiation. An increase in tumour 
permeability and blood volume, measured with perfusion CT, has been reported 
in a variety of solid tumours following radiotherapy (Harvey et al 1999). However, 
the heterogeneous group of tumours and different radiotherapy schedules make 
results difficult to compare and interpret. Tumour perfusion changes may be dose 
dependent, and may vary according to fraction size. It may also vary across 
different tumour sites, and different tumour types. In patients with rectal 
carcinoma receiving pre-operative chemo-radiotherapy, DCE-MRI measurements 
of tumour perfusion showed significant increases after the first and second week 
of treatment but not after the third and fourth week (de Vries et al 2000). In a 
separate study, also in patients with rectal carcinoma receiving pre-operative 
chemo-radiotherapy, significant decreases in perfusion CT measurements of 
blood flow were observed upon completion of treatment (Sahani et al 2005). 
However, in both these studies, the vascular changes observed might be 
confounded by the potential anti-vascular effects of the chemotherapeutic agents 
used (Miller et al 2001).
128
In conclusion, this study has demonstrated for the first time in vivo using a non- 
invasive whole tumour perfusion CT technique that fractionated radiotherapy has 
tumour vascular activity. Radiotherapy increases tumour vascular BV and K in 
human non-small cell lung cancer, and these vascular changes are more 
pronounced at the tumour rim.
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CHAPTER 5
TUMOUR VASCULAR EFFECTS OF COMBRETASTATIN A4 PHOSPHATE IN 
COMBINATION WITH RADIOTHERAPY
5.1 Introduction
Combretastatin A4 Phosphate (CA4P) is a vascular disrupting agent that targets 
immature tumour blood vessels. Phase 1 clinical trials of CA4P as a single agent 
have demonstrated reduction in tumour vascularity within four hours of patients 
receiving CA4P, with partial recovery by 24 hours (Galbraith et al 2003, 
Anderson et al 2003, Stevenson et al 2003). In animal models, CA4P causes 
haemorrhagic necrosis in the central region of tumours, and despite adequate 
doses, leaves a rim of viable tumour cells, which may re-perfuse and re-populate 
the tumour (Dark et al 1997). In contrast, radiation has shown greater tumour cell 
killing activity in better oxygenated tumour areas, such as the tumour rim (Steel 
et al 1983). The combination of radiotherapy with CA4P has been shown to 
achieve a reduction in tumour cell survival, and synergy between the two agents 
has been demonstrated in animal tumour models (Li et al 1998, Murata et al
2001). However, the potential vascular interaction between radiotherapy and 
CA4P has yet to be studied in humans.
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5.2 Aim
A phase 1b clinical trial of radiotherapy combined with CA4P in patients with 
advanced lung cancer was designed to include the in vivo assessment of the 
tumour vascular effects after radiotherapy in combination with CA4P using 
volumetric perfusion computed tomography (CT).
5.3 Patients and Methods
5.3.1 Study design
Local research ethics committee approval was obtained, with explicit approval for 
radiation exposure of patients for research purposes as required under the 
Ionising Radiation (Medical Exposure) Regulations (IR(ME)R). Each patient gave 
written informed consent; this included information on the radiation exposure 
from both the CT examinations (7.5mSv per examination), and subsequent 
radiotherapy (27Gy total dose). This Phase 1b study was primarily designed to 
evaluate the safety and toxicity of the combination of radiotherapy with CA4P. 
Functional imaging using perfusion CT was incorporated to assess the tumour 
vascular changes that occur after radiotherapy in combination with CA4P, and 
the results form the basis of this chapter.
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Patients with histologically confirmed, inoperable non-small cell lung cancer, who 
were due to receive palliative radiotherapy, were eligible for the study. In addition, 
patients must not have clinically significant cardiac abnormality including 
uncontrolled hypertension, history of angina or myocardial infarction, arrhythmias, 
or prolongation of QTc interval. Other requirements included age 18 years or 
older, World Health Organisation performance status of 0 to 2, life expectancy of 
more than 12 weeks, minimum 4 weeks interval between prior chemotherapy, 
immunotherapy, and radiotherapy and receiving CA4P, and adequate renal, 
hepatic, and haematological function. Patients were also excluded if they had 
major surgery in the preceding 4 weeks, active brain metastases, grade 2 or 
greater peripheral neuropathy, symptomatic peripheral vascular disease or 
cerebrovascular disease.
Eligible patients were recruited prospectively into two treatment cohorts with six 
patients in each cohort. All patients were treated with a course of hypo- 
fractionated palliative radiotherapy, delivering 27Gy in six fractions of 
radiotherapy over three weeks (two fractions per week). Six patients in the first 
cohort received a single 50mg/m2 dose of CA4P after the second fraction of 
radiotherapy. Six patients in the second cohort received weekly CA4P at the 
same dose after the second, fourth and sixth fractions of radiotherapy (Table 5.1).
Table 5.1 Treatment schedule for study patients receiving 
combretastatin A4 Phosphate (CA4P) at 50mg/m2 in 
combination with radiotherapy (RT) at 4.5Gy per fraction
Cohort Week Mon Tues Wed Thurs Fri Sat Sun
1 1 RT RT +
CA4P
2 RT RT
3 RT RT
2 1 RT RT+
CA4P
2 RT RT+
CA4P
3 RT RT+
CA4P
Approximately two hours after completion of radiotherapy, CA4P was 
administered intravenously over 10 minutes using a volumetric pump. The dose 
of CA4P corresponds to the weight of the free acid; the dose representing the 
free acid is equal to 90% of the dose representing the disodium salt. Thus, 
50mg/m2 of CA4P as the free acid is equivalent to a dose of 55.5mg/m2 of the 
disodium salt, which is above the threshold dose of 52mg/m2 where CA4P was
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shown to have tumour anti-vascular activity as a single agent, and is below the 
maximum tolerated dose (Galbraith et al 2003, Anderson et al 2003, Stevenson 
et al 2003). Volumetric perfusion CT scans were performed at (i) baseline, (ii) 
after the second, fourth and sixth fractions of radiotherapy prior to CA4P, (iii) four 
hours following CA4P administration to assess for acute vascular changes, and 
(iv) 72 hours after CA4P to determine the duration of the vascular response.
5.3.2 Volumetric perfusion CT
The CT methodology, image post-processing and data analysis have been 
described in Chapter 2. Apart from whole tumour vascular measurements, 
additional image analysis was carried out for both the tumour rim and the tumour 
centre in order to assess the spatial distribution of the vascular changes after 
treatment. The tumour rim was defined as the area less than 20% of the diameter 
from the tumour edge, and the tumour centre was defined as the area more than 
30% of the diameter from the tumour edge. Because of difficulty in defining the 
tumour rim and the centre at the ends of the tumour volume, analysis was only 
carried out on a single central representative 10mm tumour axial level. As before, 
Patlak analysis (1983) was used to quantify (i) transfer constant (K; 
ml/100ml/min) which provides information on permeability surface area product 
and blood flow, and (ii) relative blood volume (BV; ml/100ml) on a pixel-by-pixel 
basis.
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5.3.3 Statistical analysis
Paired t test was performed to compare mean changes in BV and K. In addition, 
Bland and Altman repeatability statistics (1986), as described in Chapter 3, were 
used to assess if an observed response following therapy is meaningful. The 
95% limits of change for a group of ‘n’ patients can be estimated from the value 
of the mean squared differences (dSD) derived from the repeatability data set 
using the following formula: (1.96*dSD)/\n. From the repeatability data derived 
previously from 17 patients, the dSD values for BV and logarithmically 
transformed K were 1.05ml/100ml and 0.13ml/100ml/min respectively. Hence, for 
a group of eight patients, any change in tumour BV of more than ±13.4%, or an 
increase in tumour K of more than 9.6%, or reduction of more than 8.8% as a 
consequence of treatment would be over and above intrinsic measurement 
variability, that is, the probability of this change being random is less than 5%. 
Similarly, for a group of four patients, any change in BV of more than ±18.9%, or 
increase in K of more than 13.9%, or reduction more than 12.2% would be 
statistically significant at the 5% level.
5.4 Results
Twelve patients were treated in the study. Four patients did not take part in the 
CT study for logistical reasons. Patients 1 and 2 were recruited before the CT 
was fully developed for clinical use. Patients 8 and 11 were treated during Bank
Holidays when the CT was unfortunately unavailable for research purposes. The 
remaining eight patients (six males, two females; mean age 66 years; six stage 
NIB, two stage IV) completed all CT scans. Thus, eight patients received CA4P 
following the second fraction of radiotherapy (9Gy total dose), and four of these 
patients received further doses of CA4P after the fourth (18Gy total dose) and 
sixth (27Gy total dose) fractions of radiotherapy. Whole tumour vascular 
measurements were performed for all scans, while vascular measurements from 
the tumour rim and centre were carried out for scans performed during the first 
week of treatment only.
5.4.1 Vascular changes from the whole tumour during the first week of 
treatment
Baseline mean tumour K and BV were 11.6ml/100ml/min and 6.8ml/100mi 
respectively. Following the second fraction of radiotherapy (9Gy total dose), 
mean K increased by 11.7% which was just greater than the 95% limits of 
change but was not significant on paired t-testing (p=0.20) (Figure 5.1). Mean BV 
increased by 10.6% (p=0.16) which was not statistically significant. Four hours 
after CA4P, there was a decrease in BV (16.4%; p=0.029), which was sustained 
to 72 hours (21.3%; p=0.025) (Figure 5.2). At four and 72 hours after CA4P, K 
decreased by 6.2% (p=0.51) and 7.7% (p=0.23) respectively which were not 
statistically significant.
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On an individual patient basis, it was observed that six of the eight patients 
achieved reductions in tumour BV (22.9%, p<0.001) four hours after CA4P 
(Figure 5.3). It was also noted that all six patients had increases in K after 
radiotherapy (23.6%, p=0.011; Figure 5.3). The two patients who did not have a 
vascular response to CA4P did not show an initial increase in tumour K following 
radiotherapy. Indeed, for all eight patients, there was a significant correlation 
between increase in K following radiotherapy and the reduction in vascular BV 
four hours following CA4P administration (r=0.77, p=0.026) (Figure 5.4). At 72 
hours after CA4P, there was a sustained reduction in tumour vascular BV of 
29.6% (p<0.001) in the same six patients.
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(a)
High K
Low K
Figure 5.1 CT images of a lung tumour from three representative axial 
levels showing coloured parametric map of transfer constant 
(K) at baseline (a) and after two fractions (9Gy total dose) of 
radiotherapy (b). Increases in K were seen predominantly at 
the rim of the tumour.
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■
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Low BV
Figure 5.2 CT images of a lung tumour from three representative axial 
levels showing coloured parametric map of tumour blood 
volume (BV) before CA4P (a), 4 hours (b), and 72 hours (c) 
after a single dose of CA4P. Reduction in BV seen after CA4P 
at 4 hours was sustained to 72 hours and most evident at the 
tumour rim.
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Figure 5.3 Line graphs showing individual changes in tumour transfer 
constant (K) after two fractions of radiotherapy (RT) (a), and 
tumour blood volume (BV) at four and 72 hours after 
combretastatin A4 Phosphate (CA4P) (b). The six patients who 
had increases in K after RT had a vascular response to CA4P
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Figure 5.4
■40 -20 0 20 40 60
% change in tumor vessel K after radiotherapy (9Gy)
Regression plot showing change in whole tumour blood 
volume (BV) after combretastatin A4 Phosphate (CA4P) 
against change in the transfer constant (K) after radiotherapy. 
Increase in K after radiotherapy correlated to reduction in BV 
after CA4P (r=0.77, p=0.026)
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5.4.2 Vascular changes in the tumour rim compared to the centre during 
the first week of treatment
Baseline tumour vascularity was spatially heterogeneous; the tumour rim 
demonstrated a higher K and BV than the tumour centre. The ratio of BV at the 
tumour rim to the tumour centre was 2.0:1. Similarly, for K, this was1.5:1. 
Following the second fraction of radiotherapy, mean K increased by 12.7% 
(p=0.36) at the tumour rim but decreased by 2.2% (p=0.84) at the centre. Four 
hours after CA4P, mean BV decreased by 32.0% (p=0.16) at the tumour rim and 
10.6% (p=0.41) at the tumour centre. At 72 hours after CA4P, a reduction in BV 
of 39.3% (p=0.097) was measured at the tumour rim, and 14.6% (p=0.15) at the 
tumour centre. Increase in K after radiotherapy correlated to reduction in BV after 
CA4P (r=0.75, p=0.020) at the tumour rim only.
Analysis was then carried out on the six patients who had a vascular response to 
CA4P. For these patients, increases in K following the second fraction of 
radiotherapy were also greater at the tumour rim than the tumour centre (34.2%, 
p=0.0073 versus 11.3%, p=0.28) (Figure 5.5). Four hours following CA4P 
administration, there was a greater reduction in BV at the tumour rim than the 
tumour centre (45.5%, p=0.035 versus 22.7%, p=0.0077) (Figure 5.5). Reduction 
in BV at the tumour rim and centre were sustained to 72 hours (51.4%, p=0.014 
versus 22.8%, p=0.012).
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Figure 5.5 Line graphs showing mean vascular changes (±1 standard 
error) at the tumour rim and the tumour centre for transfer 
constant (K) after two fractions of radiotherapy (a), and blood 
volume (BV) at four and 72 hours after combretastatin A4 
phosphate (CA4P) (b). Changes in both vascular parameters 
were greater at the tumour rim compared to the tumour centre.
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5.4.3 Vascular changes from the whole tumour during the second week of 
treatment
Following the fourth fraction of radiotherapy (18Gy total dose), mean tumour K 
and BV increased by 3.4% (p=0.59) and 33.1% (0.064) respectively. Four hours 
after receiving the second dose of CA4P, all four patients had reductions in 
tumour BV (8.4%, p=0.038), which reduced further at 72 hours after CA4P 
(31.7%, p=0.025). At the end of the second week of treatment, there was a 
reduction in BV of 28.5% (p=0.029) compared to baseline, which was also 
greater than the 95% limits of change.
5.4.4 Vascular changes from the whole tumour during the third week of 
treatment
Following the sixth fraction of radiotherapy (27Gy total dose), K decreased by 
8.4% (p=0.49), while tumour BV increased by 27.1% (p=0.049). Four and 72 
hours after the third dose of CA4P, tumour BV decreased by 8.7% (p=0.34) and 
22.2% (p=0.061) respectively. Overall, a reduction in tumour BV of 30.3% 
(p=0.044), which was also greater than the 95% limits of change, was observed 
at the end of treatment compared to baseline (Figure 5.6).
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Figure 5.6 Changes in mean (±1 standard error) tumour blood volume 
(BV) and transfer constant (K) during the course of treatment.
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5.5 Discussion
One of the advantages of vascular disrupting agents in the treatment of cancer is 
that tumour vascular endothelial cells are untransformed and do not undergo 
genetic alterations leading to resistance. However, resistance can occur when 
some tumour blood vessels escape occlusion, allowing blood flow to continue 
and adjacent tumour cells to survive. CA4P disrupts immature vessels in the 
tumour centre causing haemorrhagic necrosis, but leaves a rim of surviving cells 
that can repopulate the tumour. This might explain the lack of objective tumour 
response, and partial recovery of perfusion when used as a single agent in phase 
1 clinical trials. In order to overcome this resistance, CA4P was administered in 
combination with radiotherapy in this study.
At the dose used in this study, the vascular disrupting effect of CA4P is through 
its action on tumour endothelial cells. Within minutes of exposure to CA4P, there 
is a change in the cytoskeletal network within immature tumour endothelial cells 
resulting in a marked change in the endothelial cell shape, and an increase in 
vascular permeability. This leads to an additional increase in the already high 
interstitial fluid pressure in tumours, resulting in vascular collapse (Galbraith et al 
2001, Kanthou and Tozer 2002, Tozer et al 2005). Recent in vitro studies have 
shown that both radiation and CA4P increase tumour permeability through a 
similar effect on tumour endothelial cells, by activating the Rho/Rho kinase signal 
pathway, and causing reorganisation of actin filaments (Kanthou et al 2005).
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Tumours with greater permeability have been shown to be more susceptible to 
the effects of CA4P (Tozer et al 2001, Beauregard et al 2001). Radiotherapy, by 
increasing vessel permeability through the same pathway as CA4P, might 
therefore augment the vascular disrupting activity of CA4P. The positive 
correlation between radiation induced increase in K and reduction in BV after 
CA4P also appear to uphold the hypothesis, proposed by pre-clinical data, that 
radiotherapy may enhance the effect of CA4P.
In pre-clinical studies, the enhancement of CA4P by radiation appears to be 
dependent on timing and scheduling. In the C3H mammary carcinoma, 
improvement in tumour control was only observed when CA4P was administered 
at the same time or after radiation (Murata et al 2001, Horsman and Murata
2002). There are two possible reasons for this. Firstly, as we have shown in this 
clinical study, radiotherapy induces changes in the tumour vasculature that 
appear to increase the vascular shutdown caused by subsequent administration 
of CA4P. Secondly, CA4P when administered before radiation may induce acute 
tumour hypoxia and render the tumour radioresistant. In this clinical study, CA4P 
was administered to patients about two hours after receiving radiotherapy. 
Furthermore, the fractionated regimen used here potentially allows tumour re­
oxygenation to occur, as there is a 72 hours interval between radiation fractions. 
It was shown recently that there was significant re-perfusion and re-oxygenation 
at the periphery of the syngeneic 13762NF rat breast carcinoma by 24 hours 
following CA4P treatment (Zhao et al 2005).
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During the first week of treatment, CA4P caused a greater reduction in tumour 
BV at the tumour rim compared to the centre. This spatial distribution of vascular 
shutdown following CA4P appears inconsistent with preclinical data where CA4P 
has been shown to be more effective at the tumour centre than the rim. However, 
increases in K following 9Gy of radiation were also predominantly at the tumour 
rim; further supporting the hypothesis that radiation enhances vascular shut 
down after CA4P. At the tumour centre, increase in K following radiotherapy was 
not statistically significant (11.3%, p=0.28), while at 4 hours after CA4P 
administration, there was a significant reduction in BV (22.7%, p=0.0077). This 
explains why increase in K after radiotherapy did not significantly correlate to 
reduction in BV after CA4P at the tumour centre. This suggests that while 
radiotherapy might enhance the vascular disrupting effects of CA4P at the 
tumour rim, CA4P is able to target the vasculature at the tumour centre 
independent of the effects of radiation. The reduction in tumour vascular BV 
observed after the combination of radiotherapy and CA4P is in contrast to the 
increase in BV that has been demonstrated after radiotherapy alone in Chapter 4. 
Furthermore, the sustained vascular shutdown at 72 hours is in contrast to the 
partial recovery in tumour vascularity seen within 24 hours of single agent CA4P, 
and suggests a positive interaction between radiation and CA4P.
All four patients in the second cohort had increases in tumour K after the second 
fraction of radiotherapy, followed by a vascular response to the first dose of
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CA4P. However, the changes in K after the fourth and sixth fractions of 
radiotherapy were not statistically significant, and there was a decrease in K after 
the sixth radiation fraction. These findings are similar to the K changes after 
radiotherapy alone (Chapter 4), and might be due to establishment of equilibrium 
between vessel permeability and interstitial pressure following repeated fractions 
of radiation. Despite the small number of patients, there were significant 
reductions in mean tumour BV after the second and third doses of CA4P when 
compared to baseline. Each additional week of treatment resulted in a further 
cumulative decrease in BV; by the end of treatment, there was a 30.3% overall 
reduction in tumour BV. Increases in BV after radiotherapy were also observed 
during the second and third week of treatment, which might have contributed to 
increasing drug delivery to the tumour vessels, thus further enhancing the 
vascular disrupting effect of CA4P.
In summary, we have used a non-invasive perfusion CT technique to 
demonstrate the vascular interaction between radiation and CA4P. The positive 
correlation between increase in tumour K after radiotherapy and reduction in 
vascular BV after CA4P, together with the sustained vascular shutdown, and the 
spatial distribution of blood volume change may provide a mechanistic rationale 
for the enhanced tumour anti-vascular activity between radiation and CA4P.
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CHAPTER 6
TUMOUR VASCULAR EFFECTS OF NITRIC OXIDE SYNTHESIS INHIBITION
6.1 Introduction
Nitric oxide (NO) is an important signalling compound that is synthesised during 
the conversion of L-arginine to citrulline, catalysed by the nitric oxide synthase 
(NOS) enzymes (Alderton et al 2001). NO has complex functions in tumour 
biology, with apparently opposing roles depending on its concentration, redox 
status and the local microenvironment. Increased expression of NOS has been 
demonstrated in experimental tumour models, and higher levels of NOS 
expression in human tumours may be correlated with worse prognosis (Thomsen 
et al 1994, Cobbs et al 1995, Vakkala et al 2000, Klotz et al 1998, Fujimoto et al 
1997, Gallo et al 1998). The effects of NO on the tumour vasculature has been 
widely investigated in pre-clinical studies, and NO has been implicated in tumour 
angiogenesis, as well as maintaining the vasodilator tone of tumour blood 
vessels, thus making it an attractive target for anti-cancer therapy (Fukumara et 
al 2006, Lala et al 2001). NO has been shown to act downstream from 
angiogenic factors such as vascular endothelial growth factor (VEGF) which 
activate endothelial NOS in vascular endothelial cells (Ziche et al 1997, Veikkola 
et al 2000, Fukumara et al 2001). Competitive inhibition of NOS using analogues 
of L-arginine results in a decrease in blood flow to experimental tumours as a 
result of vasoconstriction (Tozer et al 1997). The NOS inhibitor N-nitro L-arginine
(L-NNA) has been shown in BD9 rats bearing the P22 carcinosarcoma to 
selectively reduce tumour blood flow. In man, NOS inhibition has been shown to 
increase blood pressure in healthy volunteers, and critically ill patients with septic 
shock (Haynes et al 1993, Lorente et al 1993). However, the potential anti- 
vascular tumour effects of NOS inhibition have not been investigated in patients 
with cancer.
6.2 Aim
A phase I clinical study of L-NNA in patients with cancer was designed to include 
assessment of the in vivo tumour vascular effects of L-NNA using volumetric 
perfusion CT.
6.3 Patients and Methods
6.3.1 Study Design
Local research ethics committee approval was obtained for the study and all 
patients provided written informed consent, which included information on the 
radiation exposure from the CT examinations (7.5mSv per examination). Patients 
were enrolled prospectively onto a phase 1 dose escalation study. Main inclusion 
criteria were patients >18 years old with a World Health Organization 
performance status <2 and histologically confirmed cancer. Patients with 
hypertension or any significant cardiac medical history were excluded from the
study. The starting dose was 0.1 mg/kg, escalating stepwise to 0.2mg/kg, 
0.3mg/kg, 0.5mg/kg, 0.7mg/kg and 0.9mg/kg. A total of three patients were 
studied at each of the six dose levels. L-NNA was supplied as a lyophilised 
powder and reconstituted in 0.9% sodium chloride to provide a 5.85mg/ml 
solution. All patients received a single intravenous dose of L-NNA administered 
as a one minute infusion.
Cardiovascular monitoring was carried out on all patients in the study. Pulse, 
systolic and diastolic blood pressures were monitored at five minute intervals for 
the first hour, and hourly for six hours after L-NNA. Any adverse event that 
occurred while a patient was enrolled onto the trial was recorded and graded 
according to the National Cancer Institute common toxicity criteria (CTC) version 
2.0 (Appendix 1). All patients had blood sampled for pharmacokinetic 
measurements. In addition, perfusion CT scans were performed on the final eight 
patients in the study. Scans were performed (i) prior to receiving L-NNA, (ii) one 
hour after L-NNA to measure the acute vascular changes, and (iii) 24 hours 
following L-NNA administration to determine the duration of the vascular 
response.
6.3.2 Pharmacokinetics
Blood samples in 7ml heparinised blood tubes were taken before treatment and 
at 2 minutes after the end of infusion, then at 5, 10, 15, 30, 45, 60, 75, 90, 105,
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120, 150, 180, 240, and 360 minutes. When possible, blood samples were also 
taken 24 hours after treatment. Samples were immediately placed on ice. After 
centrifugation, plasma was removed with a pipette and transferred to a -20°C 
freezer. Pharmacokinetic analysis was performed by Dr Michael Stratford at the 
Gray Cancer Institute. Concentration of L-NNA was measured using high 
performance liquid chromatography with absorbance detection using a method 
based on that of Tabrizi-Fard and Fung (1996). Half-lives were calculated by 
weighted nonlinear least squares regression, area under the curve (AUC) and 
area under the first moment curve (AUMC) were calculated using the linear 
trapezoidal rule, extrapolated to infinity using the terminal half life, clearance (Cl) 
was calculated as dose/AUC, and the volume of distribution at steady state 
(Vdss)as Cl x AUMC/AUC.
6.3.3 Volumetric perfusion CT
The CT methodology, image post-processing and data analysis have been 
described in Chapter 2. As before, Patlak analysis (1983 and 1985) was used to 
quantify (i) transfer constant (K; ml/100ml/min) which provides information on 
permeability surface area product and blood flow, and (ii) relative blood volume 
(BV; ml/100ml) on a pixel-by-pixel basis. For this study, an upgraded version of 
the prototype perfusion CT software was used, which allows the estimation of the 
percentage of non-perfused pixels. When BV was calculated as zero, these 
pixels were considered to be non-perfused, as opposed to pixels that fail to
model mathematically. These were assumed to represent non-functioning 
vessels. The percentage of non-perfused pixels in each ROI was recorded.
6.3.4 Statistical analysis
Paired t test was performed to compare mean changes in BV and K. In addition, 
Bland and Altman repeatability statistics (1986), as described in Chapter 3, were 
used to assess if an observed response following therapy is meaningful. The 
95% limits of change for a group of ‘n’ patients can be estimated from the value 
of the mean squared differences (dSD) derived from the repeatability data set 
using the following formula: (1.96*dSD)/\n. From the repeatability data derived 
previously from 17 patients, the dSD values for BV and logarithmically 
transformed K were 1.05ml/100ml and 0.13ml/100ml/min respectively. Hence, for 
a group of eight patients, any change in tumour vascular BV of more than 
±13.4% as a consequence of treatment would be over and above intrinsic 
measurement variability, that is, the probability of this change being random is 
less than 5%. Similarly, an increase in tumour vessel K of more than 9.6%, or 
reduction of more than 8.8% would be statistically significant at the 5% level.
6.4 Results
Eighteen patients (seven females and 11 males; age range 36 to 76 years; 12 
non-small cell lung, five prostate, and one cervical cancer) were recruited onto
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the study. All patients were assessed for toxicity and had plasma sampled for 
pharmacokinetic measurements. Eight patients from the final three dose levels 
(seven non-small cell lung cancer and one cervical cancer) underwent perfusion 
CT examinations.
6.4.1 Cardiovascular changes following L-NNA
A decrease of 6.1% (p<0.001) of mean pulse rate was observed by five minutes 
after L-NNA from baseline of 81.2 (SD 15.4) beats per minute to 76.2 (SD 15.3) 
beats per minute, further decreasing by 11.2% (p=0.0069) below baseline to 72.1 
(SD 15.3) beats per minute. Mean systolic blood pressure increased by 6.1% 
(p<0.001) from baseline of 133.2 (SD 19.6) mmHg to 141.4mmHg (SD 19.0) 
mmHg at 40 minutes after L-NNA. Similarly, mean diastolic blood pressure 
increased by 10.4% (p<0.001) from baseline of 75.3 (SD 8.9) mmHg to 83.2 (SD 
11.7) mmHg at 50 minutes after L-NNA. All cardiovascular changes returned to 
baseline levels by three hours after L-NNA (Figure 1). Three patients, treated at 
the 0.2mg/kg, 0.3mg/kg and 0.7mg/kg dose levels respectively, had CTC grade 1 
hypertension. Two patients had grade 1 sinus bradycardia. One patient at the 
first dose level reported transient grade 1 palpitation at 45 minutes following L- 
NNA, without 12-lead electrocardiography changes. No other adverse effects 
were observed or reported.
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Figure 6.1 Mean cardiovascular changes (± 95% confidence intervals) in 
systolic blood pressure (SBP), diastolic blood pressure (DBP) 
and pulse rate (HR) after a single dose of N-nitro L-arginine (L- 
NNA).
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6.4.2 Pharmacokinetics
In all but two patients, the peak L-NNA concentration was seen at the end of the 
infusion. L-NNA AUC increased linearly with dose from 163pmol.min.L'1 at 
0.1 mg/kg to 2150pmol.min.L~1 at 0.9mg/kg (r=0.89, p<0.001) (Figure 6.2). Peak 
L-NNA concentration (Cmax) increased linearly with dose from 2.15pM at 
0.1 mg/kg to 24.5pM at 0.9mg/kg (r=0.71, p<0.001) (Figure 6.2). Mean L-NNA 
clearance and terminal half-life for all patients was 0.0018 (SD 0.00072) L.min' 
\kg~1 and 197 (SD 82) min respectively, and was not dependent on dose. The 
mean Vdss was 0.267L.kg'1 (SD 0.092). A typical plasma profile seen after 
0.9mg/kg is shown (Figure 6.3).
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Figure 6.2 Relationship between N-nitro L-arginine (L-NNA) dose in 
mg/kg and L-NNA plasma area under the curve (AUC) (a), and 
peak concentration (b).
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Figure 6.3 Typical plasma profile after 0.9mg/kg of N-nitro L-arginine (L- 
NNA)
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6.4.3 Tumour vascular changes following L-NNA
The final eight patients recruited onto the study underwent perfusion CT 
examinations. Two patients were treated at the 0.5mg/kg dose level, three 
patients at 0.7mg/kg, and three patients at 0.9mg/kg. The mean baseline tumour 
vascular BV was 9.2 (SD 3.7) ml/100ml and mean baseline tumour vessel K was 
14.9 (SD 5.73) ml/100ml/min. One hour after receiving L-NNA, all eight patients 
had reductions in tumour vascular BV (mean 42.9%; range 12.0 to 62.1%; paired 
t-test p=0.0070), which was greater than the 95% limits of change (Figure 6.4 
and Figure 6.5). This was associated with an increase in the number of non- 
perfused tumour pixels from 7.3% at baseline to 25.1% (p=0.0089) (Figure 6.5), 
indicating a decrease in functional vascularity. Mean tumour K decreased by 
9.3% one hour after L-NNA which was just greater than the 95% limits of change 
but did not reach statistical significance on t-testing (p=0.11).
At 24 hours following L-NNA, all eight patients had sustained reductions in 
tumour vascular BV (mean 33.9%; range 6.5 to 64.9%; p=0.035), which was also 
greater than the 95% limits of change (Figure 6.5). The number of non-perfused 
pixels remained increased above baseline at 18.1% (p=0.050) (Figure 6.5). A 
10.6% increase in K was observed at 24 hours, which was greater than the 95% 
limits of change but did not reach statistical significance on paired t-testing 
(p=0.24) (Figure 6.5). There was a significant correlation between L-NNA plasma 
AUC and the reduction in tumour vascular BV at 24 hours after L-NNA (r=0.83; 
p=0.010) (Figure 6.6) but not at one hour.
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(a)
Figure 6.4 Coloured parametric maps of tumour blood volume (BV) 
representing three contiguous axial levels of a lung tumour 
before (a), and one hour after a single 0.5mg/kg infusion of N- 
nitro L-arginine (L-NNA) (b). Each pixel within the tumour map 
represents a single vascular parameter value; the colour scale 
indicates red pixels as high BV values and purple pixels as low 
BV values.
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Figure 6.5 Line graph showing tumour vascular changes for all eight 
patients at baseline and one hour after N-nitro L-arginine (L- 
NNA) and the corresponding boxplots at baseline, one hour 
and 24 hours after L-NNA for blood volume (BV) (a), 
percentage of non-enhancing pixels (b), and transfer constant 
(K) (c). Significant reductions in BV and increases in non- 
perfused pixels were observed after L-NNA. Changes in K were 
not statistically significant.
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Figure 6.6 Relationship between plasma N-nitro L-arginine (L-NNA) area 
under the curve (AUC) and reduction in tumour blood volume 
(BV) at 24 hours after L-NNA.
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6.5 Discussion
For the first time in man, the results from this study show that inhibition of NOS 
results in an acute reduction in tumour BV which is sustained to 24 hours. The 
sustained reduction in tumour vascular BV and the increase in the number of 
non-perfused pixels up to 24 hours following L-NNA are consistent with 
prolonged vascular shutdown, which has been shown to reduce tumour growth in 
animal models (Orucevic et al 1995, Camp et al 2006). This unexpected finding 
of sustained vascular shutdown could be due to endothelial cell damage and 
development of microthrombi resulting from platelet aggregation and leucocyte 
adhesion, both known effects of reduction in vascular NO (Kubes et al 1991, 
Moncada et al 1991). The observed correlation between increasing L-NNA 
plasma AUC and vascular shutdown observed at 24 hours is consistent with a 
dose effect, and not as a result of prolonged drug exposure. There was no 
correlation between vascular changes and half-life or clearance. Indeed, L-NNA 
has a terminal half-life of less than four hours, so the vascular changes seen at 
24 hours reflect the consequence of events initiated by drug exposure. There 
was no correlation between L-NNA AUC and BV reduction at one hour 
suggesting that the acute BV reduction after L-NNA might not be dependent on 
amount of drug exposure.
NO increases tumour vascularisation through the process of angiogenesis and 
this has been found to correlate with increased tumour growth (Jenkins et al
1995). NO is the final mediator of angiogenesis stimulated by VEGF, the major 
factor implicated in angiogenesis of many human tumours (Ziche et al 1997, 
Veikkola et al 2000, Fukumara et al 2001). NO has been shown to mediate 
VEGF-induced permeability in tumour vessels, although its effects are variable. 
NOS inhibition has been shown to reduce vascular permeability to albumin in 
some experimental tumour models but not others (Fukumara et al 1997). In our 
study, tumour K reductions following L-NNA were not significant, which may be 
due to the heterogeneity of NOS expression. Our results also appear consistent 
with the tumour vascular response to the anti-angiogenic agent bevacizumab 
measured using perfusion CT, where significant changes in BV but not PS were 
reported (Willett et al 2004). The reason for this is unclear; it has been suggested 
that this might be due to the balance between a reduction in vascular surface 
area and decrease in blood volume against the effects of improved extravasation 
of contrast from normalised vasculature.
To date, clinical studies using inhibitors of NO have focused on its cardiovascular 
effects. In healthy human volunteers, the NOS inhibitor N-monomethyl L-arginine 
(L-NMMA) did not have an effect on blood pressure at doses under 3mg/kg 
(infused over 20 minutes). However at doses more than 1 mg/kg (infused over 
one hour), there was a significant reduction in heart rate and cardiac index 
(Haynes et al 1993). In patients diagnosed with septic shock, 20mg/kg of L-NNA 
was shown to increase mean arterial blood pressure, associated with a decrease 
in cardiac index and oxygen delivery (Lorente et al 1993). It is noted that the
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NOS inhibitors and doses used in these two human studies are different, and L- 
NNA has been shown to be more potent than L-NMMA (Alderton et al 2001). 
Both L-NNA and L-NMMA are non-selective inhibitors of the NOS isoforms, 
although L-NNA has a minor selectivity to eNOS compared to iNOS of just under 
ten-fold (Alderton et al 2001). The role of eNOS derived NO in promoting tumour 
angiogenesis and maintaining tumour blood flow is well studied and therefore the 
vascular changes seen here are likely to be dominated by the effects of eNOS 
inhibition. A more recent randomised trial using the non-selective NOS inhibitor 
546C88 in patients with septic shock achieved adequate maintenance of mean 
blood pressure with a reduction in the requirement for conventional inotropic 
agents. However, recruitment into the study was discontinued because of 
increased mortality in the 546C88 arm (Watson et al 2004, Lopez et al 2004).
In BD9 rats bearing subcutaneous P22 carcinosarcoma, L-NNA, up to a dose of 
1 mg/kg, selectively reduced tumour blood flow, without any significant changes in 
heart rate or mean arterial blood pressure in the rat (Tozer et al 1997), 
suggesting that tumour vessels are more sensitive than normal vessels to NOS 
inhibition. The cardiovascular changes observed in our study are therefore 
consistent with previous studies of NO synthesis inhibition in both animals and 
humans, and are possibly the result of a homeostatic response to increase in 
vascular resistance caused by NOS inhibition. In this study, the significant 
reduction in tumour BV relative to the mild and self-limiting cardiovascular 
changes suggests a degree of selectivity to the effects of NOS inhibition in
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tumour vessels. This might be because tumour vessel patency is particularly 
dependent on NO (Peterson 1991), and NOS is over-expressed in tumours, thus 
the inhibition of this potent vasodilator results in vascular collapse due to the 
immature tumour vascular walls and high interstitial fluid pressure (Boucher et al 
1990). However, the cardiovascular system is subjected to tightly regulated 
homeostatic controls and cardiovascular changes are not the ideal marker to 
determine selectivity to NOS inhibition. CT can potentially be used to measure 
changes in BV and K in normal tissues, thus estimating the effects of L-NNA on 
the peripheral vascular system. Most of the patients in this study had lung 
tumours, and the most consistent normal tissue included in the scan plane was 
the erector spinae muscle. However, measurement repeatability for skeletal 
muscle measurements is quite variable, with coefficient of variation ranging from 
27 to 70%, making it very difficult to assess vascular changes reliably (Goh et al 
2006).
In summary, the results from this study have demonstrated that NO plays a role 
in maintaining tumour blood supply and that inhibition of NO synthesis results in 
a sustained reduction in tumour BV at doses that are well tolerated, providing 
early clinical evidence that NOS inhibition has tumour anti-vascular activity in 
cancer patients.
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CHAPTER 7
CONCLUDING DISCUSSION
The arsenal in the treatment of cancer now includes chemotherapy, radiotherapy, 
immunotherapy, antibody, and gene therapy. With the recognition that growth of 
solid tumours is dependent on its blood supply, the last few years have seen an 
increase in the use of vascular targeting drugs in the clinic. A greater 
understanding of tumour vascular biology has led to the development of vascular 
disrupting agents that selectively destroy existing tumour vessels and anti- 
angiogenic agents that prevent new vessel formation. Many of these novel 
agents have shown enhancement of anti-tumour activity when combined with 
conventional treatment modalities such as radiation and cytotoxics. There is also 
evidence that radiotherapy and chemotherapy may exert their anti-tumour effects 
partially through damage to the tumour vasculature.
Functional imaging techniques, such as perfusion CT, are increasingly used to 
quantify the tumour vascularity in vivo. A significant limitation of perfusion CT as 
an in vivo clinical technique has been its inability to quantify vascular 
measurements for a large tumour volume without a significant radiation burden. It 
is well recognised that the tumour microcirculation is spatially heterogeneous. A 
conventional single level scanning technique that only assesses a limited tumour 
volume is unrepresentative of the tumour as a whole, and consequently, might be 
prone to measurement variability. As the aim of this research was to describe the
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vascular changes after anti-cancer therapy in whole human tumours, we needed 
to develop a scanning technique that could encompass a large tumour volume 
and depict this spatial heterogeneity, yet be a straightforward and clinically 
repeatable technique. We were aided by developments in multi-detector CT 
technology enabling faster scanning with isotropic resolution, thus allowing us to 
encompass the entire tumour volume in such a manner to allow quantification of 
blood volume and vascular leakage.
We found that the measurements obtained provided a more accurate 
representation of the spatial heterogeneity of tumour vasculature. More 
importantly, this whole tumour technique improves on measurement repeatability 
when compared to conventional single level techniques, increasing confidence 
that any changes observed following therapy are real, and not simply due to the 
intrinsic variability of the tumour microcirculation. This improvement in 
repeatability reflects, to a certain extent, the care that was taken to minimise 
variability from technical aspects. Patients were educated carefully prior to each 
scan to ensure the breath-holding technique was optimal, the same senior 
radiographers performed each scan, and the scans were supervised by a 
consultant CT radiologist with experience of perfusion CT techniques to ensure 
proper patient positioning and adequate anatomical coverage. Also, the patients 
recruited onto this study had lung cancer, and suffered with varying degrees of 
dyspnoea. It is truly a credit to their helpfulness, resolve, and good humour that 
such reliable results were achieved.
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Further developments are being carried out on the CT technique. The isotropic 
resolution of current multi-detector CT scanners allows vascular measurements 
to be obtained from sagittal and coronal imaging planes following reconstructions 
of the native axial CT images. For perfusion CT to be truly volumetric, vascular 
measurements should be consistent regardless of which plane the 
measurements are derived from, thus has the potential for the development of a 
true 3-dimensional vascular measurement technique. This CT technique has 
many potential applications in addition to therapeutic assessment. For example, 
this technique can potentially be integrated into sophisticated radiotherapy 
planning systems. Major advances in radiation therapy have resulted from 
improved imaging techniques that can define anatomical volumes more 
accurately. The introduction of intensity modulated radiotherapy where the dose 
is varied across the beam of radiotherapy enables different doses to be given to 
different parts of the volume at the same time. Therefore, varying radiation doses 
can be administered across the tumour volume depending on the biological 
characteristics within the tumour. Clinical trials are currently being conducted to 
assess whether biological information derived from functional imaging can assist 
in defining the tumour volume during radiotherapy planning, and ultimately, 
improve patient outcome (ClinicalTrials.gov identifier NCT00122252).
Radiotherapy has been shown to cause tumour vascular changes in human lung 
cancer. Fractionated radiotherapy increases tumour vascular leakage and blood
volume, especially at the tumour rim. A better understanding of the in vivo 
changes in tumour vascularity after ionising radiation is clinically relevant. The 
vascular effects of radiotherapy may influence radio-sensitivity of both tumours 
and normal tissues with potential implications for acute and late radiation side 
effects (Anscher et al 2005). Most radical radiotherapy is now given in 
combination with chemotherapy; novel radiation schedules are also being 
developed incorporating new agents such as monoclonal antibodies and vascular 
targeting drugs. The therapeutic success of these combinations is dependent on 
its scheduling (Glynne-Jones et al 2002, Zips et al 2003, Williams et al 2004), 
and a better understanding of the tumour vascular changes after radiotherapy 
may better guide the timing of both chemotherapy and other novel drugs.
The vascular disrupting agent CA4P selectively destroys the tumour vasculature 
by exploiting the morphological and functional differences between normal and 
tumour blood vessels. It is currently being studied in a phase 1 trial combined 
with radiotherapy. The results presented here have described the mechanistic 
vascular interaction between CA4P and radiation, and demonstrated potential 
enhancements of anti-vascular activity between the two treatments. CA4P when 
combined with radiotherapy causes a sustained reduction in tumour blood 
volume, which is in contrast to the partial recovery in perfusion and blood flow 
seen after single agent CA4P, and in contrast to the increase in blood volume 
seen after radiation alone. These initial findings provide the basis for further 
clinical studies using this novel combination. Currently, CA4P in combination with
172
radiotherapy is being offered to additional cohorts of patients with different 
tumour sites including prostate and head and neck cancers. Dose escalation will 
be carried out such that each subsequent cohort of patients will receive either a 
greater dose of CA4P, or radiation, or both. Functional imaging will continue to 
be used to evaluate the vascular responses after treatment, and it will be 
interesting to see if the higher doses and different tumour sites result in a greater 
enhancement of tumour anti-vascular activity.
For the first time in man, the NOS inhibitor L-NNA has been shown to cause a 
significant and sustained reduction in tumour vascular blood volume, providing 
clinical evidence that NO plays a role in maintaining tumour blood supply. 
Although there is probably limited potential in retarding tumour growth using NOS 
inhibitors alone, the sustained tumour vascular shutdown after just a single dose 
of L-NNA appear to show promise for its use as a novel vascular targeting agent. 
However, the biological role of NO in cancer remains unclear. Future studies 
incorporating direct measurements of NO biosynthesis and NOS activity will 
provide corroborating data on the potential of NOS inhibition as a vascular 
targeting anti-cancer agent. The effects of inhibitors of specific NOS isoforms as 
well as the potential for anti-angiogenic activity by NOS inhibition in man also 
remains to be fully evaluated.
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There is pre-clinical evidence that NO exerts a protective effect on endotheiial 
cells against CA4P, and combining CA4P with NOS inhibitors results in 
enhanced vascular disrupting activity and cytotoxicity, even in CA4P resistant 
tumour models (Parkins et al 2000, Davis et al 2002). There is clearly potential 
for combining CA4P with NOS inhibitors such as L-NNA, although care has to be 
taken to closely monitor the possible cardiovascular effects of this combination, 
and further pre-clinical studies are needed. The role of NO as a hypoxic cell 
radiosensitiser and as a mediator of chemosensitivity in tumour cells has also 
been previously discussed. Thus, further investigation into the use of NO, and 
NOS inhibitors as cancer therapeutics, and in combination with radiotherapy, 
chemotherapy, anti-angiogenic and vascular disrupting agents are warranted.
While this work has demonstrated that functional imaging can be used reliably to 
assess the tumour vasculature, further studies will be needed to show that 
tumour vascular changes observed after treatment with vascular targeting drugs 
correlate with clinical response in terms of survival or even with conventional 
response criteria in terms of tumour shrinkage. Such data will be useful in 
confirming the value of functional imaging in clinical practice, and more 
importantly, will allow one to define the level and duration of vascular change 
needed to improve clinical outcome after vascular targeting therapy.
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In conclusion, the vascular effects of cancer treatment in whole tumours can be 
measured using a repeatable, non-invasive perfusion CT technique. The results 
presented here have provided further evidence that targeting the tumour 
vasculature is a promising approach to the treatment of cancer. These findings 
will hopefully expand our knowledge of tumour vascular biology, and stimulate 
the development of new therapeutic strategies for cancer.
APPENDIX 1
National Cancer Institute common toxicity criteria (CTC) version 2.0
Hypertension
Grade 0 None
Grade 1 Asymptomatic, transient increase by >20mmHg 
(diastolic) or to >150/100 if previously within normal 
limits (WNL); not requiring treatment
Grade 2 Recurrent or persistent or symptomatic increase by 
>20mmHg (diastolic) or to >150/100 if previously WNL; 
not requiring treatment
Grade 3 Requiring therapy or more intensive therapy than 
previously
Grade 4 Hypertensive crisis
Palpitations
Grade 0 None
Grade 1 Present
Grade 2 -
Grade 3 
Grade 4
-
-
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Sinus bradycardia
Grade 0
L
Grade 1 
Grade 2 
Grade 3 
Grade 4
None
asymptomatic, not requiring treatment
symptomatic, but not requiring treatment 
symptomatic and requiring treatment 
life-threatening (e.g. arrhythmia associated withT 
congestive heart failure, hypotension, syncope, shock)
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